selected publications
-
academic article
-
Parakh SKing DGan HKScott AM. Current Development of Monoclonal Antibodies in Cancer Therapy.
Recent Results in Cancer Research.
214:1-70.
2020
Full text if available -
Emmett LTang RNandurkar RHHruby GRoach PJWatts JACusick TKneebone AHo BChan Lvan Leeuwen PScheltema MNguyen AYin CScott ATang CMcCarthy MFullard KRoberts MFrancis RStricker P. 3-year freedom from progression following 68GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi-center trial..
Journal of Nuclear Medicine.
60.
2019
Full text if available -
Emmett LMetser UBauman GHicks RJWeickhardt ADavis IDPunwani SPond GRChua SS-CHo BJohnston EPouliot FScott A. A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance and Patient Outcomes.
Journal of Nuclear Medicine.
60:794-800.
2019
Full text if available -
Yap MLMcFadyen JDWang XZiegler MChen YCWillcox ANowell CJScott AMSloan EKHogarth PMPietersz GAPeter K. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases.
Theranostics.
9:1154-1169.
2019
Full text if available -
Kramer GMYaqub MVargas HASchuit RWindhorst ADvan den Eertwegh Avan der Veldt ABergman ABurnazi ELewis JSChua SS-CStaton KBeattie BJHumm JLDavis IDWeickhardt AScott AMorris MJHoekstra OSLammertsma AA. Assessment of simplified methods for quantification of 18F-FDHT uptake in patients with metastatic castration-resistant prostate cancer.
Journal of Nuclear Medicine.
60:1221-1227.
2019
Full text if available -
Lassman ABRoberts-Rapp LSokolova ISong MPestova EKular RMullen CZha ZLu XGomez EBhathena AMaag DKumthekar PGan HKScott AMGuseva MHolen KDAnsell PJvan den Bent MJ. Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.
Clinical Cancer Research.
25:3259-3265.
2019
Full text if available -
Davalos Salas MMontgomery MKReehorst CNightingale RNg IAnderton HAl-Obaidi SLesmana AScott CIoannidis PKalra HKeerthikumar STogel LRigopoulos AGong SWilliams DSYoganantharaja PBell-Anderson KMathivanan SGibert YHiebert SScott AMWatt MJMariadason JM. Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity.
Nature Communications.
10.
2019
Full text if available -
Chia PLScott AMJohn T. Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma.
Expert Opinion on Drug Delivery.
16:441-451.
2019
Full text if available -
Lee STBurvenich IScott AM. Novel Target Selection for Nuclear Medicine Studies.
Seminars in Nuclear Medicine.
49:357-368.
2019
Full text if available -
Orellana LThorne AHLema RGustavsson JParisian ADHospital ACordeiro TNBernadó PScott AMBrun-Heath ILindahl ECavenee WKFurnari FBOrozco M. Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope.
Proceedings of the National Academy of Sciences of USA.
116:10009-10018.
2019
Full text if available -
Thilakasiri PHuynh JPoh ARTan CWNero TLTran KParslow ACAfshar-Sterle SBaloyan DHannan NJBuchert MScott AMGriffin MDWHollande FParker MWPutoczki TLErnst MChand AL. Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth.
EMBO Molecular Medicine.
11.
2019
Full text if available -
Lassman ABvan den Bent MJGan HKReardon DKumthekar PButowski NLwin ZMikkelson TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HWalbert TScott AMGomez ELee H-JRoberts-Rapp LXiong HAnsell PJBain EHolen KDMagg DMerrell R. Safety and efficacy of depatuxizumab mafodotin +
temozolomide in patients with EGFR-amplified,
recurrent glioblastoma: results from an international
phase I multicenter trial.
Neuro-Oncology.
21:106-114.
2019
Full text if available -
Shekhar TMBurvenich IJGHarris MARigopoulos AZanker DSpurling AParker BSWalkley CRScott AMHawkins CJ. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
BMC Cancer.
19.
2019
Full text if available -
Metser UChua SS-CHo BPunwani SJohnston EPouliot FTau NHawsawy AAnconina RBauman GHicks RJWeickhardt ADavis IDPond GScott ATunariu NSidhu HEmmett LM. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy..
Journal of Nuclear Medicine.
60:1253-1258.
2019
Full text if available -
Phillips ACBoghaert ERVaidya KSFalls HDMitten MJDeVries PJBenatuil LHsieh C-MMeulbroek JAPanchal SCBuchanan FGDurbin KRVoorbach MJReuter DRMudd SRLoberg LIRalston SLCao DGan HKScott AMReilly EB. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Molecular Cancer Therapeutics.
17:795-805.
2018
Full text if available -
Parslow ACClayton AHALock PScott AM. Confocal Microscopy Reveals Cell Surface Receptor Aggregation Through
Image Correlation Spectroscopy.
Journal of Visualized Experiments.
2018:1-8.
2018
Full text if available -
Li HZeitelhofer MNilsson ILiu XAllan LGloria BPerani AMurone CCatimel BNeville AMScott FEScott AMEriksson U. Development of monoclonal anti-PDGF-CC antibodies as tools for investigating human tissue expression and for blocking PDGF-CC induced PDGFRα signalling in vivo.
PLoS ONE.
13:1-20.
2018
Full text if available -
Binder ZAThorne AHBakas SWileyto EPBilello MAkbari HRathore SHa SMZhang LFerguson CJDahiya SBi WLReardon DAIdbaih AFelsberg JHentschel BWeller MBagley SJMorrissette JJDNasrallah MPMa JZanca CScott AMOrellana LDavatzikos CFurnari FBO'Rourke DM. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
Cancer Cell.
34:163-177.e7.
2018
Full text if available -
Owen CEPoon AMTLee STYap LPZwar RBMcMenamin CMLam SKLLiew DFLPathmaraj KKemp AScott AMBuchanan RRC. Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica.
Rheumatology.
57:345-353.
2018
Full text if available -
Burvenich IJGFarrugia WLiu ZMakris DKing DGloria BPerani AAllan LCScott ARamsland PA. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Biochemical Journal.
475:2179-2190.
2018
Full text if available -
Ayati NLee STZakavi RPathmaraj KAl-Qatawna LPoon AScott AM. Long-Acting Somatostatin Analog Therapy Differentially Alters 68 Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions.
Journal of Nuclear Medicine.
59:223-227.
2018
Full text if available -
Lau LFMurone CWilliams DSStandish RLee STChristophi CScott AMMuralidharan V. Metabolic response evaluation for colorectal liver metastases and correlation to pathologic response and tumour markers..
ANZ Journal of Surgery.
88:E108-E113.
2018
Full text if available -
Nadebaum DLee SNikfarjam MScott AM. Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68 Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature.
World Journal of Nuclear Medicine.
17:195-197.
2018
Full text if available -
Roswall PBocci MBartoschek MLi HKristiansen GJansson SLehn SSjölund JReid SLarsson CEriksson PAnderberg CCortez ESaal LHOrsmark-Pietras CCordero EHaller BKHäkkinen JBurvenich IJGLim EOrimo AHöglund MRydén LMoch HScott AMEriksson UPietras K. Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling.
Nature Medicine.
24:463-473.
2018
Full text if available -
McKay MJTaubman KLForoudi FLee STScott AM. Molecular Imaging Using PET/CT for Radiation Therapy Planning for Adult Cancers: Current Status and Expanding Applications.
International Journal of Radiation: Oncology - Biology - Physics.
102:783-791.
2018
Full text if available -
Burvenich IJGParakh SLee F-TGuo NLiu ZGan HKRigopoulos AO'Keefe GJGong SJGoh YWTochon-Danguy HScott FEKotsuma MHirotani KSenaldi GScott AM. Molecular imaging of T cell co-regulator factor B7-H3 with Zr-89-DS-5573a.
Theranostics.
8:4199-4209.
2018
Full text if available -
Hafeez UGan HKScott AM. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases.
Current Opinion in Pharmacology.
41:114-121.
2018
Full text if available -
Zeitelhofer MLi HAdzemovic MZNilsson IMuhl LScott AMEriksson U. Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CChum mice.
PLoS ONE.
13:1-16.
2018
Full text if available -
Burvenich IJGParakh SParslow ACLee STGan HKScott AM. Receptor occupancy imaging studies in oncology drug development.
American Association of Pharmaceutical Scientists (AAPS) Journal.
20:1-16.
2018
Full text if available -
Vargas HAKramer GMScott AMWeickhardt AMeier AAParada NBeattie BJHumm JLStaton KDZanzonico PBLyashchenko SKLewis JSYaqub MSosa REvan den Eertwegh AJDavis IDAckermann UPathmaraj KSchuit RCWindhorst ADChua SWeber WALarson SMScher HILammertsma AAHoekstra OMorris MJ. Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study.
Journal of Nuclear Medicine.
59:1516-1523.
2018
Full text if available -
Gan HKReardon DALassman ABMerrell Rvan den Bent MButowski NLwin ZWheeler HFichtel LScott AMGomez EJFischer JMandich HXiong HLee H-JMunasinghe WPRoberts-Rapp LAAnsell PJHolen KDKumthekar P. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Neuro-Oncology.
20:838-847.
2018
Full text if available -
Roach PJFrancis REmmett LHsiao EKneebone AHruby GEade TNguyen QAThompson BDCusick TMcCarthy MTang CHo BStricker PDScott AM. The Impact of 68 Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study.
Journal of Nuclear Medicine.
59:82-88.
2018
Full text if available -
Chang AYDao TGejman RSJarvis CAScott ADubrovsky LMathias MDKorontsvit TZakhaleva VCurcio MHendrickson RCLiu CScheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.
Journal of Clinical Investigation.
127:2705-2718.
2017
Full text if available -
Gan HKvan den Bent MLassman ABReardon DAScott AM. Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Nature Reviews Clinical Oncology.
14:695-707.
2017
Full text if available -
Björnmalm MThurecht KJMichael MScott AMCaruso F. Bridging Bio–Nano Science and Cancer Nanomedicine.
ACS Nano.
11:9594-9613.
2017
Full text if available -
Laval MMarshall KMSachinidis JScott AEutick MBaldwin GS. Complexes of gastrin with In3+, Ru3+ or Ga3+ ions are not recognised by the cholecystokinin 2 receptor.
Journal of Biological Inorganic Chemistry.
22:999-1006.
2017
Full text if available -
Reardon DALassman ABvan den Bent MKumthekar PMerrell RScott AMFichtel LSulman EPGomez EFischer JLee H-JMunasinghe WXiong HMandich HRoberts-Rapp LAnsell PHolen KDGan HK. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma..
Neuro-Oncology.
19:965-975.
2017
Full text if available -
van den Bent MGan HKLassman ABKumthekar PMerrell RButowski NLwin ZMikkelsen TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HWalbert TScott AMGomez ELee H-JRoberts-Rapp LXiong HBain EAnsell PJHolen KDMaag DReardon DA. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Cancer Chemotherapy and Pharmacology.
80:1209-1217.
2017
Full text if available -
Charmsaz SAl-Ejeh FYeadon TMMiller KJSmith FMStringer BWMoore ASLee F-TCooper LTStylianou CYarranton GTWoronicz JScott AMLackmann MBoyd AW. EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
Leukemia.
31:1779-1787.
2017
Full text if available -
Parakh SGan HKParslow ACBurvenich IJGBurgess AWScott AM. Evolution of anti-HER2 therapies for cancer treatment.
Cancer Treatment Reviews.
59:1-21.
2017
Full text if available -
Yeung YLau DKChionh FTran HTse JWTWeickhardt AJNikfarjam MScott AMTebbutt NCMariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Molecular Oncology.
11:1130-1142.
2017
Full text if available -
Orcutt KDAdams GPWu AMSilva MDHarwell CHoppin JMatsumura MKotsuma MGreenberg JScott AMBeckman RA. Molecular simulation of receptor occupancy and tumor penetration of an antibody and smaller scaffolds: application to molecular imaging.
Molecular Imaging and Biology.
19:656-664.
2017
Full text if available -
Di Biase MAZalesky AO'Keefe GLaskaris LBaune BTWeickert CSOlver JMcGorry PDAmminger GPNelson BScott AMHickie IBanati RTurkheimer FYaqub MEverall IPPantelis CCropley V. PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia.
Translational Psychiatry.
7:1-8.
2017
Full text if available -
Rivalland GScott AMJohn T. Standard of care in immunotherapy trials: challenges and considerations.
Human Vaccines and Immunotherapeutics.
13:2164-2178.
2017
Full text if available -
Charmsaz SScott AMBoyd AW. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.
Experimental Hematology.
54:31-39.
2017
Full text if available -
Eissmann MAtapattu LSaha NChheang CEissman MFXu KVail MEHii LLlerena CLiu ZHorvay KAbud HEKusebauch UMoritz RLDing B-SCao ZRafii SErnst MScott AMNikolov DBLackmann MJanes PW. An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth.
Journal of Experimental Medicine.
213:1741-1757.
2016
Full text if available -
Parslow ACParakh SLee F-TGan HKScott AM. Antibody-Drug Conjugates for Cancer Therapy.
Biomedicines.
4:1-17.
2016
Full text if available -
Parakh SParslow ACGan HKScott AM. Antibody-mediated delivery of therapeutics for cancer therapy.
Expert Opinion on Drug Delivery.
13:401-419.
2016
Full text if available -
Jahani-Asl AYin HSoleimani VDHaque TLuchman HAChang NCSincennes MCPuram SVScott AMLorimer IAJPerkins TJLigon KLWeiss SRudnicki MABonni A. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.
Nature Neuroscience.
19.
2016
Full text if available -
Burvenich IJGFarrugia WLee FTCatimel BLiu ZMakris DCao DO'Keefe GJBrechbiel MWKing DSpirkoska VAllan LCRamsland PAScott AM. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
mAbs.
8:775-786.
2016
Full text if available -
Gan HKBurgess AWParslow ACScott AM. Dual targeting of EGFR: Ready for prime time?.
Translational Cancer Research.
5:S18-S21.
2016
Full text if available -
Burvenich IJGLee F-TO'Keefe GJMakris DCao DGong SRigopoulos AAllan LCBrechbiel MWLiu ZRamsland PAScott AM. Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers.
EJNMMI Research.
6:1-13.
2016
Full text if available -
Laurens EYeoh SDRigopoulos AO'Keefe GJTochon-Danguy HJChong LWWhite JMScott AMAckermann U. Fluorine-18 radiolabeling of a nitrophenyl sulfoxide and its evaluation in an SK-RC-52 model of tumor hypoxia.
Journal of Labelled Compounds and Radiopharmaceuticals.
59:416-423.
2016
Full text if available -
Ackermann ULewis JSYoung KMorris MJWeickhardt ADavis IDScott AM. Fully automated synthesis of [18F]fluoro-dihydrotestosterone ([18F]FDHT) using the FlexLab module.
Journal of Labelled Compounds and Radiopharmaceuticals.
59:424-428.
2016
Full text if available -
Higginbotham JNZhang QJeppesen DKScott AMManning HCOchieng JFranklin JLCoffey RJ. Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting.
Journal of Extracellular Vesicles.
5.
2016
Full text if available -
Burvenich IJGLee F-TGuo NGan HKRigopoulos AParslow ACO'Keefe GJGong SJTochon-Danguy HRudd SEDormelly PSKotsuma MOhtsuka TSenaldi GScott AM. In vitro and in vivo evaluation of 89Zr-DS-8273a as a theranostic for anti-death receptor 5 therapy.
Theranostics.
6:2225-2234.
2016
Full text if available -
Lee FTBurvenich IJGGuo NKocovski PTochon-Danguy HAckermann UO'Keefe GJGong SRigopoulos ALiu ZGan HKScott AM. L-Tyrosine Confers Residualizing Properties to a D-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies.
Molecular Imaging.
15:1-9.
2016
Full text if available -
Burvenich IJGParakh SGan HKLee F-TGuo NRigopoulos ALee S-TGong SO'Keefe GJTochon-Danguy HKotsuma MHasegawa JSenaldi GScott AM. Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with Zr-89-DS-8895a.
Journal of Nuclear Medicine.
57:974-980.
2016
Full text if available -
Fahey FHBom HH-SChiti AChoi YYHuang GLassmann MLaurin NMut FNunez-Miller RO'Keeffe DPradhan PScott AMSong SSoni NUchiyama MVargas L. Standardization of administered activities in pediatric nuclear medicine: a report of the first Nuclear Medicine Global Initiative project, part 2 - current standards and the path toward global standardization.
Journal of Nuclear Medicine.
57:1148-1157.
2016
Full text if available -
Chia PLRussell PAScott AMJohn T. Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.
Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care.
16:1235-1245.
2016
Full text if available -
Solomon BJDesai JRosenthal MMcArthur GAPattison STPattison SLMacDiarmid JBrahmbhatt HScott AM. A First-Time-In-Human Phase i Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells.
PLoS ONE.
10.
2015
Full text if available -
Reilly EBPhillips ACBuchanan FGKingsbury GZhang YMeulbroek JACole TBDevries PJFalls HDBeam CGu JDigiammarino ELPalma JPDonawho CKGoodwin NCScott AM. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody.
Molecular Cancer Therapeutics.
14:1411-1451.
2015
Full text if available -
Chang JHLim Joon DDavis IDLee STHiew CYEsler SGong SJWada MClouston DO'Sullivan RGoh YPBolton DScott AMKhoo V. Comparison of [<sup>11</sup>C]choline positron emission tomography with T2- and diffusion-weighted magnetic resonance imaging for delineating malignant intraprostatic lesions.
International Journal of Radiation: Oncology - Biology - Physics.
92:438-445.
2015
Full text if available -
Baird SKAllan LRenner CScott FEScott AM. Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways.
Clinical and Experimental Metastasis.
32:507-516.
2015
Full text if available -
Whittle JRLickliter JDGan HKScott AMSimes JSolomon BJMacDiarmid JABrahmbhatt HRosenthal MA. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.
Journal of Clinical Neuroscience.
22:1889-1894.
2015
Full text if available -
Williams BBTebbutt NCBuchert MPutoczki TLDoggett KBao SJohnstone CNMasson FHollande FBurgess AWScott AMErnst MHeath JK. Glycoprotein A33 deficiency: A new mouse model of impaired intestinal epithelial barrier function and inflammatory disease.
Disease Models and Mechanisms.
8:805-815.
2015
Full text if available -
Baird SKRigopoulos ACao DAllan LRenner CScott FEScott AM. Integral membrane protease fibroblast activation protein sensitizes fibrosarcoma to chemotherapy and alters cell death mechanisms.
Apoptosis: an international journal on programmed cell death.
20:1483-1498.
2015
Full text if available -
Greening DWLee STJi HSimpson RJRigopoulos AMurone CFang CGong SO'Keefe GScott AM. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
Oncotarget.
6:38166-38180.
2015
Full text if available -
Zanzonico PCarrasquillo JAPandit-Taskar NO'Donoghue JAHumm JLSmith-Jones PRuan SDivgi CScott AMKemeny NEFong YWong DScheinberg DRitter GJungbluth AOld LJLarson SM. PET-based compartmental modeling of I-124-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.
European Journal of Nuclear Medicine and Molecular Imaging.
42:1700-1706.
2015
Full text if available -
Ciprotti MTebbutt NCLee F-TLee S-TGan HKMcKee DCO'Keefe GJGong SJChong GHopkins WChappell BScott FEBrechbiel MWTse ANJansen MMatsumura MKotsuma MWatanabe RVenhaus RBeckman RAGreenberg JScott AM. Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.
Journal of Clinical Oncology.
33:2609-2616.
2015
Full text if available -
Kao YHGoodwin MLee STLichtenstein MScott AM. Scientific basis of personalised tomographic radiation planning for radioembolisation: A form of brachytherapy planning.
Journal of Medical Imaging and Radiation Oncology.
59:617-618.
2015
Full text if available -
Fahey FHBom HHSChiti AChoi YYHuang GLassmann MLaurin NMut FNuñez-Miller RO'Keeffe DPradhan PScott AMSong SSoni NUchiyama MVargas L. Standardization of Administered activities in pediatric nuclear medicine: A report of the first Nuclear Medicine Global Initiative project, part 1 - Statement of the Issue and a review of available resources.
Journal of Nuclear Medicine.
56:646-651.
2015
Full text if available -
Dingjan TSpendlove IDurrant LGScott AMYuriev ERamsland PA. Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies.
Molecular Immunology.
67:75-88.
2015
Full text if available -
Johnston AJMurphy KTJenkinson LLaine DEmmrich KFaou PWeston RJayatilleke KMSchloegel JTalbo GCasey JLLevina VWong WW-LDillon HSahay THoogenraad JAnderton HHall CSchneider PTanzer MFoley MScott AMGregorevic PLiu SYBurkly LCLynch GSSilke JHoogenraad NJ. Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival.
Cell.
162:1365-1378.
2015
Full text if available -
Lee STScott AM. The current role of pet/ct in radiotherapy planning.
Current Radiopharmaceuticals.
8:38-44.
2015
Full text if available -
Dao TPankov DScott AKorontsvit TZakhaleva VXu YXiang JYan SDe Morais Guerreiro MDVeomett NDubrovsky LCurcio MDoubrovina EPonomarev VLiu CO'Reilly RJScheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.
Nature Biotechnology.
33:1079-1086.
2015
Full text if available -
North AJHayne DJSchieber CPrice KWhite ARCrouch PJRigopoulos AO'Keefe GJTochon-Danguy HScott AMWhite JMAckermann UDonnelly PS. Toward Hypoxia-Selective Rhenium and Technetium Tricarbonyl Complexes.
Inorganic Chemistry: including bioinorganic chemistry.
54:9594-9610.
2015
Full text if available -
Weickhardt AJWilliams DSLee CKChionh FSimes JMurone CWilson KParry MMAsadi KScott AMPunt CJANagtegaal IDPrice TJMariadason JMTebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
British Journal of Cancer.
113:37-45.
2015
Full text if available -
Mertens LSMir MCScott AMLee STFioole-Bruining AVegt EVogel WVManecksha RBolton DDavies IHorenblas SVan Rhijn BWGLawrentschuk N. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
Urology.
83:393-399.
2014
Full text if available -
Dubrovsky LPankov DBrea EJDao TScott AYan SO'Reilly RJLiu CScheinberg DA. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.
Blood.
123:3296-3304.
2014
Full text if available -
Ardipradja KYeoh SDAlt KO'Keefe GRigopoulos AHowells DWScott AMPeter KAckerman UHagemeyer CE. Detection of activated platelets in a mouse model of carotid artery thrombosis with 18F-labeled single-chain antibodies.
Nuclear Medicine and Biology.
41:229-237.
2014
Full text if available -
Chang JHLim Joon DLee STHiew CYEsler SGong SJWada MClouston DO'Sullivan RGoh YPTochon-Danguy HChan JGBolton DScott AMKhoo VDavis ID. Diffusion-weighted MRI, 11C-choline PET and 18F- fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.
European Radiology.
24:715-722.
2014
Full text if available -
Janes PWSlape CIFarnsworth RHAtapattu LScott AMVail ME. EphA3 biology and cancer.
Growth Factors.
32:176-189.
2014
Full text if available -
Tan GJSBerlangieri SULee STScott AM. FDG PET/CT in the liver: lesions mimicking malignancies.
Abdominal Imaging.
39:187-195.
2014
Full text if available -
Ackermann UPlougastel LWichmann CGoh YWYeoh SDPoniger SSTochon-Danguy HJScott AM. Fully automated synthesis and coupling of [18F]FBEM to glutathione using the iPHASE FlexLab module.
Journal of Labelled Compounds and Radiopharmaceuticals.
57:115-120.
2014
Full text if available -
To CFarnsworth RHVail MEChheang CGargett CEMurone CLlerena CMajor ATScott AMJanes PWLackmann M. Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth.
PLoS ONE.
9.
2014
Full text if available -
Ackermann UPlougastel LGoh YWYeoh SDScott AM. Improved synthesis of [18F]FLETT via a fully automated vacuum distillation method for [18F]2-fluoroethyl azide purification.
Applied Radiation and Isotopes.
94:72-76.
2014
Full text if available -
Wong PKLee STMurone CEng JLawrentschuk NBerlangieri SUPathmaraj KO'Keefe GJSachinidis JByrne AJBolton DMDavis IDScott AM. In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET.
Asia Oceania Journal of Nuclear Medicine and Biology.
2:3-11.
2014
-
Lau LFWilliams DSLee STScott AMChristophi CMuralidharan V. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.
Annals of Surgical Oncology.
21:2420-2428.
2014
Full text if available -
Scott AMTiganis T. Pioneer of Eph biology and therapeutics: Martin Lackmann (1956–2014).
Growth Factors.
32:171-173.
2014
Full text if available -
Ciprotti MChong GGan HKChan AMurone CMacGregor DLee FTJohns TGHeath JKErnst MBurgess AWScott AM. Quantitative intratumoural microdistribution and kinetics of 131I-huA33 antibody in patients with colorectal carcinoma.
EJNMMI Research.
4:1-10.
2014
Full text if available -
Laurens EYeoh SDRigopoulos ACao DCartwright GAO'Keefe GJTochon-Danguy HJWhite JMScott AMAckermann U. Radiolabelling and evaluation of a novel sulfoxide as a PET imaging agent for tumor hypoxia.
Nuclear Medicine and Biology.
41:419-425.
2014
Full text if available -
Alt KPaterson BMArdipradja KSchieber CBuncic GLim BPoniger SSJakoby BWang XOkeefe GJTochon-Danguy HJScott AMAckermann UPeter KDonnelly PSHagemeyer CE. Single-Chain antibody conjugated to a cage amine chelator and labeled with positron-emitting copper-64 for diagnostic imaging of activated platelets.
Molecular Pharmaceutics.
11:2855-2863.
2014
Full text if available -
Herbertson RATebbutt NCLee FTGill SChappell BCavicchiolo TSaunder TO'Keefe GJPoon ALee STMurphy RHopkins WScott FEScott AM. Targeted chemoradiation in metastatic colorectal cancer: A phase i trial of 131i-hua33 with concurrent capecitabine.
Journal of Nuclear Medicine.
55:534-539.
2014
Full text if available -
Vail MEMurone CTan AHii LAbebe DJanes PWLee FTBaer MPalath VBebbington CYarranton GLlerena CGaric SAbramson DCartwright GScott AMLackmann M. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
Cancer Research.
74:4470-4481.
2014
Full text if available -
Lee STJi HGreening DWSpeirs RWHRigopoulos APillay VMurone CVitali AStühler KJohns TGCorner GAMariadason JMSimpson RJScott AM. Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts.
Growth Factors.
31:154-164.
2013
Full text if available -
Lawrentschuk NLee STScott AM. Current role of PET, CT, MR for invasive bladder cancer.
Current Urology Reports.
14:84-89.
2013
Full text if available -
Chang JHWada MAnderson NJLim Joon DLee STGong SJGunawardana DHSachinidis JO'Keefe GGan HKKhoo VScott AM. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using 18F-FMISO PET: A biological modeling study.
Acta Oncologica.
52:1723-1729.
2013
Full text if available -
Burvenich IJGLee FTCartwright GAO'Keefe GJMakris DCao DGong SChueh ACMariadason JMBrechbiel MWBeckman RAFujiwara KVon Roemeling RScott AM. Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008.
Clinical Cancer Research.
19:5984-5993.
2013
Full text if available -
Ritchie DSNeeson PJKhot APeinert STai TTainton KChen KShin MWall DMHönemann DGambell PWesterman DAHaurat JWestwood JAScott AMKravets LDickinson MTrapani JASmyth MJDarcy PKKershaw MHPrince HM. Persistence and efficacy of second generation CAR T Cell against the LeY Antigen in acute myeloid leukemia.
Molecular Therapy.
21:2122-2129.
2013
Full text if available -
Dao TYan SVeomett NPankov DZhou LKorontsvit TScott AWhitten JMaslak PCasey ETan TLiu HZakhaleva VCurcio MDoubrovina EO'Reilly RJLiu CScheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.
Science Translational Medicine.
5:1-11.
2013
Full text if available -
Tauro BJGreening DWMathias RAJi HMathivanan SScott AMSimpson RJ. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.
Methods.
56:293-304.
2012
Full text if available -
Atapattu LSaha NLlerena CVail MEScott AMNikolov DBLackmann MJanes PW. Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function.
Journal of Cell Science.
125:6084-6093.
2012
Full text if available -
Scott AMWolchok JDOld LJ. Antibody therapy of cancer.
Nature Reviews: Cancer.
12:278-287.
2012
Full text if available -
Weickhardt AJPrice TJChong GGebski VPavlakis NJohns TGAzad ASkrinos EFluck KDobrovic ASalemi RScott AMMariadason JMTebbutt NC. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Journal of Clinical Oncology.
30:1505-1512.
2012
Full text if available -
Mcleish ARLee STByrne AJScott AM. Impact of 18F-FDG-PET in decision making for liver metastectomy of colorectal cancer.
ANZ Journal of Surgery.
82:30-35.
2012
Full text if available -
Chang JHLim Joon DLee STGong SJAnderson NJScott AMDavis IDClouston DBolton DHamilton CSKhoo V. Intensity modulated radiation therapy dose painting for localized prostate cancer using C-choline positron emission tomography scans.
International Journal of Radiation: Oncology - Biology - Physics.
83:e692-e697.
2012
Full text if available -
Walker FRothacker JHenderson CNice ECCatimel BZhang HHScott AMBailey MFOrchard SGAdams TELiu ZGarrett TPJClayton AHABurgess AW. Ligand binding induces a conformational change in epidermal growth factor receptor dimers.
Growth Factors.
30:394-409.
2012
Full text if available -
Shimoni OPostma AYan YScott AMHeath JKNice ECZelikin ANCaruso F. Macromolecule functionalization of disulfide-bonded polymer hydrogel capsules and cancer cell targeting.
ACS Nano.
6:1463-1472.
2012
Full text if available -
Haro KJScott ACScheinberg DA. Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells.
Blood.
120:2087-2097.
2012
Full text if available -
Scott AMAllison JPWolchok JD. Monoclonal antibodies in cancer therapy.
Cancer Immunity.
12.
2012
-
Greenall SAGherardi ELiu ZDonoghue JFVitali AALi QMurphy RIamele LScott AMJohns TG. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET..
PLoS ONE.
7.
2012
Full text if available -
Lawrentschuk NSasges DTasevski RAbouassaly RScott AMDavis ID. Oncology health information quality on the internet: A multilingual evaluation.
Annals of Surgical Oncology.
19:706-713.
2012
Full text if available -
Lee STLawrentschuk NScott AM. PET in prostate and bladder tumors.
Seminars in Nuclear Medicine.
42:231-246.
2012
Full text if available -
Scott AMMitchell PLO'Keefe GSaunder THicks RJPoon ABaum CBrega NMcCarthy TJToner GC. Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies.
EJNMMI Research.
2.
2012
Full text if available -
Muralidharan VKwok MLee STLau LScott AMChristophi C. Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases.
Journal of Nuclear Medicine.
53:1345-1351.
2012
Full text if available -
Fischer EChaitanya KWuëst TWadle AScott AMVan Den Broek MSchibli RBauer SRenner C. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies.
Clinical Cancer Research.
18:6208-6218.
2012
Full text if available -
Laurens EYeoh SDRigopoulos ACao DCartwright GAO'Keefe GJTochon-Danguy HJWhite JMScott AMAckermann U. Radiolabelling and evaluation of novel haloethylsulfoxides as PET imaging agents for tumor hypoxia.
Nuclear Medicine and Biology.
39:871-882.
2012
Full text if available -
Clemons NJWang DHCroagh DTikoo AFennell CMMurone CScott AMNeil Watkins DPhillips WA. Sox9 drives columnar differentiation of esophageal squamous epithelium: A possible role in the pathogenesis of Barrett's esophagus.
American Journal of Physiology: Gastrointestinal and Liver Physiology.
303:G1335-G1346.
2012
Full text if available -
Johnston APRKamphuis MMJSuch GKScott AMNice ECHeath JKCaruso F. Targeting cancer cells: Controlling the binding and internalization of antibody-functionalized capsules.
ACS Nano.
6:6667-6674.
2012
Full text if available -
Gan HKBurgess AWClayton AHAScott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.
Cancer Research.
72:2924-2930.
2012
Full text if available -
Dhomen NSMariadason JTebbutt NScott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Critical Reviews in Oncogenesis.
17:31-50.
2012
Full text if available -
Perani AGloria BWang DBuffier A-SBerteau OEsteban GSmyth FEScott AM. Evaluation of an online biomass probe to monitor cell growth and cell death.
BMC Proceedings.
5:P16.
2011
Full text if available -
Perani AGloria BWang DMurphy RSingh HKSmyth FEScott AM. Impact on product quality of high productive GS-CHO cell lines.
BMC Proceedings.
5:P17.
2011
Full text if available -
Cvrljevic ANAkhavan DWu MMartinello PFurnari FBJohnston AJGuo DPike LCavenee WKScott AMMischel PSHoogenraad NJJohns TG. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.
Journal of Cell Science.
124:2938-2950.
2011
Full text if available -
Ackermann UYeoh SDSachinidis JIPoniger SSScott AMTochon-Danguy HJ. A simplified protocol for the automated production of succinimidyl 4-[ 18F]fluorobenzoate on an IBA Synthera module.
Journal of Labelled Compounds and Radiopharmaceuticals.
54:671-673.
2011
Full text if available -
Pillay VGan HKScott AM. Antibodies in oncology.
New Biotechnology.
28:518-529.
2011
Full text if available -
Murri-Plesko MTHulikova AOosterwijk EScott AMZortea AHarris ALRitter GOld LBauer SSwietach PRenner C. Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX.
Behavioural Processes.
657:173-183.
2011
Full text if available -
Binns DSPirzkall AYu WCallahan JMileshkin LConti PScott AMMacFarlane DFine BMHicks RJ. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
European Journal of Nuclear Medicine and Molecular Imaging.
38:642-650.
2011
Full text if available -
Kozer NKelly MPOrchard SBurgess AWScott AMClayton AHA. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
Biochemistry.
50:3581-3590.
2011
Full text if available -
Feigen MLee STLawford CChurcher KZupan EScott AMHamilton C. Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and 18F-FDG PET/CT scan correlation.
Journal of Medical Imaging and Radiation Oncology.
55:320-332.
2011
Full text if available -
Ymer SIGreenall SACvrljevic ACao DXDonoghue JFChandana Epa VScott AMAdams TEJohns TG. Glioma specific extracellular missense mutations in the first cysteine rich region of epidermal growth factor receptor (EGFR) initiate ligand independent activation.
Cancers.
3:2032-2049.
2011
Full text if available -
Chang JHJoon DLLee STGong SJScott AMDavis IDClouston DBolton DHamilton CSKhoo V. Histopathological correlation of 11C-choline PET scans for target volume definition in radical prostate radiotherapy.
Radiotherapy and Oncology.
99:187-192.
2011
Full text if available -
Ma YKowolik CMSwiderski PMKortylewski MYu HHorne DAJove RCaballero OLSimpson AJGLee FTPillay VScott AM. Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.
ACS Chemical Biology.
6:962-970.
2011
Full text if available -
Lawrentschuk NLee FTJones GRigopoulos AMountain AO'Keefe GPapenfuss ATBolton DMDavis IDScott AM. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT.
Urologic Oncology: seminars and original investigations.
29:411-420.
2011
Full text if available -
Barnett SBaste JMMurugappan KTog CBerlangieri SScott ASeevanayagam SKnight S. Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: The impact of 2-18F-fluoro-2-deoxy-d-glucose positron emission tomogram mediastinal staging.
European Journal of Cardio-Thoracic Surgery.
39:96-101.
2011
Full text if available -
Beckman RAVon Roemeling RScott AM. Monoclonal antibody dose determination and biodistribution into solid tumors.
Therapeutic Delivery.
2:333-344.
2011
Full text if available -
Burton KJChappell BMLee STBerlangieri SUThomas DLScott AMRowe CC. Multi-modality confirmation of splenosis.
Gamma Gazette.
1:32-33.
2011
-
Ramsland PAFarrugia WBradford TMSardjono CTEsparon STrist HMPowell MSTan PSCendron ACWines BDScott AMHogarth PM. Structural basis for FcγRIIa recognition of human IgG and formation of inflammatory signaling complexes.
Journal of Immunology.
187:3208-3217.
2011
Full text if available -
Ackermann USigmund DYeoh SDRigopoulos AO'Keefe GCartwright GWhite JScott AMTochon-Danguy HJ. Synthesis of 2-[(4-[ 18F]Fluorobenzoyloxy)methyl]-1,4- naphthalenedione from 2-hydroxymethyl 1,4-naphthoquinone and 4-[ 18F]fluorobenzoic acid using dicyclohexyl carbodiimide.
Journal of Labelled Compounds and Radiopharmaceuticals.
54:788-794.
2011
Full text if available -
Ackermann UO'Keefe GLee STRigopoulos ACartwright GSachinidis JIScott AMTochon-Danguy HJ. Synthesis of a [18F]fluoroethyltriazolylthymidine radiotracer from [18F]2-fluoroethyl azide and 5-ethynyl-2′-deoxyuridine.
Journal of Labelled Compounds and Radiopharmaceuticals.
54:260-266.
2011
Full text if available -
Kamphuis MMJJohnston APRSuch GKDam HHEvans RAScott AMNice ECHeath JKCaruso F. Targeting of Cancer Cells Using Click-Functionalized Polymer Capsules.
Journal of the American Chemical Society.
132:15881-15883.
2010
Full text if available -
Hricak HChoi BIScott AMSugimura KMuellner Avon Schulthess GKReiser MFGraham MMDunnick NRLarson SM. Global Trends in Hybrid Imaging.
Radiology.
257:498-506.
2010
Full text if available -
Johns TGMcKay MJCvrljevic ANGan HKTaylor CXu HSmyth FEScott AM. MAb 806 Enhances the Efficacy of Ionizing Radiation in Glioma Xenografts Expressing the de2-7 Epidermal Growth Factor Receptor.
International Journal of Radiation: Oncology - Biology - Physics.
78:572-578.
2010
Full text if available -
Barber TWTing Lee SLim EKiat Lim HScott AM. Benign Ectopic Multinodular Thyroid Tissue in the Submandibular Region With a Coexistent Normotopic Multinodular Thyroid Gland Harboring Papillary Thyroid Cancer.
Clinical Nuclear Medicine.
35:618-619.
2010
Full text if available -
Azad AChionh FScott AMLee STBerlangieri SUWhite SMitchell PL. High Impact of 18F-FDG-PET on Management and Prognostic Stratification of Newly Diagnosed Small Cell Lung Cancer.
Molecular Imaging and Biology.
12:443-451.
2010
Full text if available -
Olver JSO'Keefe GJones GRBurrows GDTochon-Danguy HJAckermann UScott AMNorman TR. Dopamine D1 receptor binding in the anterior cingulate cortex of patients with obsessive–compulsive disorder.
Psychiatry Research: Neuroimaging.
183:85-88.
2010
Full text if available -
Lee FTO'Keefe GJGan HKMountain AJJones GRSaunder THSagona JRigopoulos ASmyth FEJohns TGGovindan SVGoldenberg DMOld LJScott AM. Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using 124I-IMP-R4-Labeled Antibody ch806.
Journal of Nuclear Medicine.
51:967-972.
2010
Full text if available -
Lawrentschuk NScott AMDavis ID. Potential of imaging biomarkers for characterization of renal masses.
Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care.
10:781-786.
2010
Full text if available -
Lawrentschuk NDavis IDBolton DMScott AM. Functional imaging of renal cell carcinoma.
Nature Reviews: Urology.
7:258-266.
2010
Full text if available -
Peinert SPrince HMGuru PMKershaw MHSmyth MJTrapani JAGambell PHarrison SScott AMSmyth FEDarcy PKTainton KNeeson PRitchie DSHönemann D. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.
Gene Therapy (Basingstoke).
17:678-686.
2010
Full text if available -
Vervoort LBurvenich IStaelens SDumolyn CWaegemans EVan Steenkiste MBaird SKScott AMDe Vos F. Preclinical Evaluation of Monoclonal Antibody 14C5 for Targeting Pancreatic Cancer.
Cancer Biotherapy and Radiopharmaceuticals.
25:193-205.
2010
Full text if available -
McCarthy CMVanLaeken NLennox PScott AMPusic AL. The efficacy of Artecoll injections for the augmentation of nipple projection in breast reconstruction..
Eplasty: open access journal of plastic and reconstructive surgery.
10:e7.
2010
-
Thiel MWolfs M-JBauer SWenning ASBurckhart TSchwarz ECScott AMRenner CHoth M. Efficiency of T-cell costimulation by CD80 and CD86 cross-linking correlates with calcium entry.
Immunology.
129:28-40.
2010
Full text if available -
Farrugia WScott AMRamsland PA. A Possible Role for Metallic Ions in the Carbohydrate Cluster Recognition Displayed by a Lewis Y Specific Antibody.
PLoS ONE.
4:e7777-e7777.
2009
Full text if available -
Herbertson RATebbutt NCLee F-TMacFarlane DJChappell BMicallef NLee S-TSaunder THopkins WSmyth FEWyld DKBellen JSonnichsen DSBrechbiel MWMurone CScott AM. Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers.
Clinical Cancer Research.
15:6709-6715.
2009
Full text if available -
Lee STGhanem MHerbertson RABerlangieri SUByrne AJTabone KMitchell PKnight SRFeigen MScott AM. Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma.
Molecular Imaging and Biology.
11:473-479.
2009
Full text if available -
Gan HKLappas MCao DXCvrljevdic AScott AMJohns TG. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization.
Journal of Cell and Molecular Medicine.
13:3993-4001.
2009
Full text if available -
Bauer SOosterwijk-Wakka JCAdrian NOosterwijk EFischer EWüest TStenner FPerani ACohen LKnuth ADivgi CJäger DScott AMRitter GOld LJRenner C. Targeted therapy of renal cell carcinoma: Synergistic activity of cG250-TNF and IFNg.
International Journal of Cancer.
125:115-123.
2009
Full text if available -
Azad AChionh FScott AWhite SMitchell PL. Staging (18)FDG-PET in newly diagnosed small cell lung cancer (SCLC): 15-year institutional experience..
Journal of Clinical Oncology.
27:e19044.
2009
-
Pillay VAllaf LWilding ALDonoghue JFCourt NWGreenall SAScott AMJohns TG. The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases.
Neoplasia.
11:448-IN2.
2009
Full text if available -
Olver JSO'Keefe GJones GRBurrows GDTochon-Danguy HJAckermann UScott ANorman TR. Dopamine D1 receptor binding in the striatum of patients with obsessive–compulsive disorder.
Journal of Affective Disorders.
114:321-326.
2009
Full text if available -
Gill SCosolo WHerbertson RABerlangieri SUScott AM. Medullary carcinoma of the thyroid in a patient with colon cancer and a rising carcinoembryonic antigen level.
Internal Medicine Journal.
39:264-265.
2009
Full text if available -
Westwood JAMurray WKTrivett MHaynes NMSolomon BMileshkin LBall DMichael MBurman AMayura-Guru PTrapani JAPeinert SHönemann DMiles Prince HScott AMSmyth MJDarcy PKKershaw MH. The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum.
Journal of Immunotherapy.
32:292-301.
2009
Full text if available -
Garrett TPJBurgess AWGan HKLuwor RBCartwright GWalker FOrchard SGClayton AHANice ECRothacker JCatimel BCavenee WKOld LJStockert ERitter GAdams TEHoyne PAWittrup DChao GCochran JRLuo CLou MHuyton TXu YFairlie WDYao SScott AMJohns TG. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.
Proceedings of the National Academy of Sciences of USA.
106:5082-5087.
2009
Full text if available -
Herbertson RAScarsbrook AFLee STTebbutt NScott AM. Established, emerging and future roles of PET/CT in the management of colorectal cancer.
Clinical Radiology.
64:225-237.
2009
Full text if available -
Chatterton BEHo Shon IBaldey ALenzo NPatrikeos AKelley BWong DRamshaw JEScott AM. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study.
European Journal of Nuclear Medicine and Molecular Imaging.
36:354-361.
2009
Full text if available -
Scott AMGunawardana DHWong JKirkwood IHicks RJHo Shon IRamshaw JERobins P. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study.
European Journal of Nuclear Medicine and Molecular Imaging.
36:347-353.
2009
Full text if available -
Macfarlane DSocrates AEisenberg PLarcos GRoach PGerometta MSmart RTsui WScott AM. Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab′ fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial.
European Journal of Nuclear Medicine and Molecular Imaging.
36:250-259.
2009
Full text if available -
Adams TEKoziolek EJHoyne PHBentley JDLu LLovrecz GWard CWLee FTScott AMNash ADRothacker JNice ECBurgess AWJohns TGAdams TEKoziolek EJHoyne PHBentley JDLu LLovrecz GWard CWLee FTScott AMNash ADRothacker JNice ECBurgess AWJohns TG. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activityin vivo.
Growth Factors.
27:141-154.
2009
Full text if available -
Kelly MPLee STLee F-TSmyth FEDavis IDBrechbiel MWScott AM. Therapeutic efficacy of177Lu-CHX-A″-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
The Prostate.
69:92-104.
2009
Full text if available -
He JO'Keefe GJGong SJJones GSaunder TScott AMGeso M. A Novel Method for Respiratory Motion Gated With Geometric Sensitivity of the Scanner in 3D PET.
IEEE Transactions on Nuclear Science.
55:2557-2565.
2008
Full text if available -
Scott AMGunawardana DHBartholomeusz DRamshaw JELin P. PET Changes Management and Improves Prognostic Stratification in Patients with Head and Neck Cancer: Results of a Multicenter Prospective Study.
Journal of Nuclear Medicine.
49:1593-1600.
2008
Full text if available -
Scott AMGunawardana DHKelley BStuckey JGByrne AJRamshaw JEFulham MJ. PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study.
Journal of Nuclear Medicine.
49:1451-1457.
2008
Full text if available -
Kelly MPLee F-TTahtis KPower BESmyth FEBrechbiel MWHudson PJScott AM. Tumor Targeting by a Multivalent Single-Chain Fv (scFv) Anti-Lewis Y Antibody Construct.
Cancer Biotherapy and Radiopharmaceuticals.
23:411-424.
2008
Full text if available -
Westwood JAMurray WKTrivett MShin ANeeson PMacGregor DPHaynes NMTrapani JAMayura-Guru PFox SPeinert SHonemann DPrince HMRitchie DScott AMSmyth FESmyth MJDarcy PKKershaw MH. Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.
Gene Therapy (Basingstoke).
15:1056-1066.
2008
Full text if available -
Nguyen BTJoon DLKhoo VQuong GChao MWada MJoon MLSee AFeigen MRykers KKai CZupan EScott A. Assessing the impact of FDG-PET in the management of anal cancer.
Radiotherapy and Oncology.
87:376-382.
2008
Full text if available -
Kageyama SKitano SHirayama MNagata YImai HShiraishi TAkiyoshi KScott AMMurphy RHoffman EWOld LJKatayama NShiku H. Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel.
Cancer Science.
99:601-607.
2008
Full text if available -
Lee STTan TPoon AMTToh HBGill SBerlangieri SUKraft EByrne AJPathmaraj KO’Keefe GJTebbutt NScott AM. Role of Low-dose, Noncontrast Computed Tomography from Integrated Positron Emission Tomography/Computed Tomography in Evaluating Incidental 2-Deoxy-2-[F-18]fluoro-d-glucose-avid Colon Lesions.
Molecular Imaging and Biology.
10:48-53.
2008
Full text if available -
Perera RMZoncu RJohns TGPypaert MLee F-TMellman IOld LJToomre DKScott AM. Internalization, Intracellular Trafficking, Biodistribution of Monoclonal Antibody 806: A Novel Anti-Epidermal Growth Factor Receptor Antibody.
Neoplasia.
9:1099-1110.
2007
Full text if available -
Lee STScott AM. Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole.
Seminars in Nuclear Medicine.
37:451-461.
2007
Full text if available -
Lee STBerlangieri SUPoon AMTMitchell PPathmaraj KTabone KByrne AJO?Keefe GJKnight SRClarke CPScott AM. Prevalence of occult metastatic disease in patients undergoing18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
Internal Medicine Journal.
0:070521010100001-???.
2007
Full text if available -
Herbertson RALee STTebbutt NScott AM. The expanding role of PET technology in the management of patients with colorectal cancer.
Annals of Oncology.
18:1774-1781.
2007
Full text if available -
Scott AMLee FTTebbutt NHerbertson RGill SSLiu ZSkrinos EMurone CSaunder THChappell BPapenfuss ATPoon AMTHopkins WSmyth FEMacGregor DCher LMJungbluth AARitter GBrechbiel MWMurphy RBurgess AWHoffman EWJohns TGOld LJ. Correction for Scott et al., A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
Proceedings of the National Academy of Sciences of USA.
104:15965-15965.
2007
Full text if available -
Krug LMMilton DTJungbluth AAChen L-CQuaia EPandit-Taskar NNagel AJones JKris MGFinn RSmith-Jones PScott AMOld LDivgi C. Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels.
Journal of Thoracic Oncology.
2:947-952.
2007
Full text if available -
Davis IDWiseman GALee FTGansen DNHopkins WPapenfuss ATLiu ZMoynihan TJCroghan GAAdjei AAHoffman EWIngle JNOld LJScott AM. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma..
Cancer Immunity.
7:13.
2007
-
Davis IDLiu ZSaunders WLee FTSpirkoska VHopkins WSmyth FEChong GPapenfuss ATChappell BPoon ASaunder THHoffman EWOld LJScott AM. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma..
Cancer Immunity.
7:14.
2007
-
Cortez CTomaskovic-Crook EJohnston APRScott AMNice ECHeath JKCaruso F. Influence of Size, Surface, Cell Line, and Kinetic Properties on the Specific Binding of A33 Antigen-Targeted Multilayered Particles and Capsules to Colorectal Cancer Cells.
ACS Nano.
1:93-102.
2007
Full text if available -
Davis IDWiseman GALee FTGansen DNHopkins WPapenfuss ATLiu ZMoynihan TJCroghan GAAdjei AAHoffman EWIngle JNOld LJScott AM. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
Cancer Immunity.
7.
2007
-
Davis IDLiu ZSaunders WLee FTSpirkoska VHopkins WSmyth FEChong GPapenfuss ATChappell BPoon ASaunder THHoffman EWOld LJScott AM. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
Cancer Immunity.
7:177S-177S.
2007
-
He JO'Keefe GJJones GSaunder TGong SJGeso MScott AM. Evaluation of Geometrical Sensitivity for Respiratory Motion Gating by GATE and NCAT Simulation.
Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings.
2007:4165-4168.
2007
Full text if available -
Scott AMTebbutt NLee F-TCavicchiolo TLiu ZGill SPoon AMTHopkins WSmyth FEMurone CMacGregor DPapenfuss ATChappell BSaunder THBrechbiel MWDavis IDMurphy RChong GHoffman EWOld LJ. A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen.
Clinical Cancer Research.
13:3286-3292.
2007
Full text if available -
He JO'Keefe GJones GSaunder TGong SScott AGeso M. SU-FF-I-106: Simulation of Respiratory Motion Gating Using GATE and NCAT.
Medical Physics.
34:2362-2362.
2007
Full text if available -
Cebon JFindlay MHargreaves CStockler MThompson PBoyer MRoberts SPoon AScott AMKalff VGaras GDowling ACrawford DRing JBasser RStrickland AMacdonald GGreen MNowak ADickman BDhillon HGebski V. Erratum: Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
British Journal of Cancer.
96:1154-1154.
2007
Full text if available -
Johns TGPerera RMVernes SCVitali AACao DXCavenee WKScott AMFurnari FB. The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization.
Clinical Cancer Research.
13:1911-1925.
2007
Full text if available -
Scott AMLee F-TTebbutt NHerbertson RGill SSLiu ZSkrinos EMurone CSaunder THChappell BPapenfuss ATPoon AMTHopkins WSmyth FEMacGregor DCher LMJungbluth AARitter GBrechbiel MWMurphy RBurgess AWHoffman EWJohns TGOld LJ. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
Proceedings of the National Academy of Sciences of USA.
104:4071-4076.
2007
Full text if available -
Gan HKWalker FBurgess AWRigopoulos AScott AMJohns TG. The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers.
Journal of Biological Chemistry.
282:2840-2850.
2007
Full text if available -
Yücel MBrewer WJHarrison BJFornito AO'Keefe GJOlver JScott AMEgan GFVelakoulis DMcGorry PDPantelis C. Anterior cingulate activation in antipsychotic-naïve first-episode schizophrenia.
Acta Psychiatrica Scandinavica.
115:155-158.
2007
Full text if available -
Lawrentschuk NDavis IDBolton DMScott AM. Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: Current practice.
International Journal of Urology.
14:89-95.
2007
Full text if available -
Lawrentschuk NBolton DDavis IScott A. Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship.
Current Medical Imaging Reviews.
3:17-26.
2007
Full text if available -
Li DJi HZaghlul SMcNamara KLiang M-CShimamura TKubo STakahashi MChirieac LRPadera RFScott AMJungbluth AACavenee WKOld LJDemetri GDWong K-K. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas.
Journal of Clinical Investigation.
117:346-352.
2007
Full text if available -
Kitano SKageyama SNagata YMiyahara YHiasa ANaota HOkumura SImai HShiraishi TMasuya MNishikawa MSunamoto JAkiyoshi KKanematsu TScott AMMurphy RHoffman EWOld LJShiku H. HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan.
Clinical Cancer Research.
12:7397-7405.
2006
Full text if available -
Lawrentschuk NPoon AMTScott AM. Fluorine-18 Fluorothymidine: A New Positron Emission Radioisotope for Renal Tumors.
Clinical Nuclear Medicine.
31:788-789.
2006
Full text if available -
Cherk MHFoo SSPoon AMTKnight SRMurone CPapenfuss ATSachinidis JISaunder THCO'Keefe GJScott AM. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F- fluoromisonidazole and 18F-FDG PET.
Journal of Nuclear Medicine.
47:1921-1926.
2006
-
Belhocine TZScott AMEven-Sapir EUrbain JLEssner R. Role of nuclear medicine in the management of cutaneous malignant melanoma.
Journal of Nuclear Medicine.
47:957-967.
2006
-
Sakamoto JOriuchi NMochiki EAsao TScott AMHoffman EWJungbluth AAMatsui TLee FTPapenfuss AKuwano HTakahashi TEndo KOld LJ. A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.
Cancer Science.
97:1248-1254.
2006
Full text if available -
Falzon CLAckermann USpratt NTochon-Danguy HJWhite JHowells DScott AM. F-18 labelledN,N-bis-haloethylamino-phenylsulfoxides — a new class of compounds for the imaging of hypoxic tissue.
Journal of Labelled Compounds and Radiopharmaceuticals.
49:1089-1103.
2006
Full text if available -
Harrison BJYücel MShaw MKyrios MMaruff PBrewer WJPurcell RVelakoulis DStrother SCScott AMNathan PJPantelis C. Evaluating brain activity in obsessive–compulsive disorder: Preliminary insights from a multivariate analysis.
Psychiatry Research: Neuroimaging.
147:227-231.
2006
Full text if available -
Michael MThompson MHicks RJMitchell PLEllis AMilner ADDi Iulio JScott AMGurtler VHoskins JMClarke SJTebbut NCFoo KJefford MZalcberg JR. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination.
Journal of Clinical Oncology.
24:4228-4235.
2006
Full text if available -
Cortez CTomaskovic-Crook EJohnston APRRadt BCody SHScott AMNice ECHeath JKCaruso F. Targeting and Uptake of Multilayered Particles to Colorectal Cancer Cells.
Advanced Materials.
18:1998-2003.
2006
Full text if available -
Macfarlane DJSmart RCTsui WWGerometta MEisenberg PRScott AM. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′.
European Journal of Nuclear Medicine and Molecular Imaging.
33:648-656.
2006
Full text if available -
LAWRENTSCHUK NATHANDAVIS IANDBOLTON DAMIENMSCOTT ANDREWM. Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship.
BJU International.
97:916-922.
2006
Full text if available -
LAWRENTSCHUK NATHANDAVIS IANDBOLTON DAMIENMSCOTT ANDREWM. Positron emission tomography and molecular imaging of the prostate: an update.
BJU International.
97:923-931.
2006
Full text if available -
Ellis AGDoherty MMWalker FWeinstock JNerrie MVitali AMurphy RJohns TGScott AMLevitzki AMcLachlan GWebster LKBurgess AWNice EC. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.
Biochemical Pharmacology.
71:1422-1434.
2006
Full text if available -
Kelly MPLee FTSmyth FEBrechbiel MWScott AM. Enhanced efficacy of 90Y-radiolabeled anti-lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Journal of Nuclear Medicine.
47:716-725.
2006
-
Essner RBelhocine TScott AMEven-Sapir E. Novel Imaging Techniques in Melanoma.
Surgical Oncology Clinics of North America.
15:253-283.
2006
Full text if available -
Cher LMMurone CLawrentschuk NRamdave SPapenfuss AHannah AO'Keefe GJSachinidis JIBerlangieri SUFabinyi GScott AM. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
Journal of Nuclear Medicine.
47:410-418.
2006
-
Ackermann UBlanc PFalzon CLIssa WWhite JTochon-Danguy HJSachinidis JIScott AM. Synthesis of 11C labelled methyl esters: transesterification of enol esters versus BF3 catalysed esterification—a comparative study.
Radiation Physics and Chemistry.
75:48-52.
2006
Full text if available -
Lawrentschuk NRigopoulos ALee F-TDavis IDScott AMBolton DM. Xenografting Tumour beneath the Renal Capsule Using Modern Surgical Equipment.
European Surgical Research: clinical and experimental surgery.
38:340-346.
2006
Full text if available -
Westwood JASmyth MJTeng MWLMoeller MTrapani JAScott AMSmyth FECartwright GAPower BEHonemann DPrince HMDarcy PKKershaw MH. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.
Proceedings of the National Academy of Sciences of USA.
102:19051-19056.
2005
Full text if available -
Rowe CO'Keefe GScott AMTochon-Danguy HT. Positron emission tomography in neuroscience.
MedicaMundi.
49:9-16.
2005
-
Roberts FOGunawardana DHPathmaraj KWallace AU PLMi TBerlangieri SUO'Keefe GJRowe CCScott AM. Radiation dose to PET technologists and strategies to lower occupational exposure.
Journal of Nuclear Medicine Technology.
33:44-47.
2005
-
Yuriev EFarrugia WScott AMRamsland PA. Three-dimensional structures of carbohydrate determinants of Lewis system antigens: Implications for effective antibody targeting of cancer.
Immunology and Cell Biology.
83:709-717.
2005
Full text if available -
Hicks RJRischin DFisher RBinns DScott AMPeters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent.
European Journal of Nuclear Medicine and Molecular Imaging.
32:1384-1391.
2005
Full text if available -
Ollenberger GPByrne AJBerlangieri SURowe CCPathmaraj KReutens DCBerkovic SFScheffer IEScott AM. Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy.
European Journal of Nuclear Medicine and Molecular Imaging.
32:1311-1316.
2005
Full text if available -
Lawrentschuk NPoon AMTFoo SSPutra LGJMurone CDavis IDBolton DMScott AM. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.
BJU International.
96:540-546.
2005
Full text if available -
Yap KKYap KSKByrne AJBerlangieri SUPoon AMitchell PKnight SRClarke PCHarris ATauro ARowe CCScott AM. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
European Journal of Nuclear Medicine and Molecular Imaging.
32:1033-1040.
2005
Full text if available -
Scott AGan HPerera RM. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity.
Clinical Cancer Research.
11:6390-6399.
2005
Full text if available -
Vearing CLee F-TWimmer-Kleikamp SSpirkoska VTo CStylianou CSpanevello MBrechbiel MBoyd AWScott AMLackmann M. Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents.
Cancer Research.
65:6745-6754.
2005
Full text if available -
Scott AM. Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter?.
Journal of Clinical Oncology.
23:4567-4569.
2005
Full text if available -
Davis IDChen WJackson HParente PShackleton MHopkins WChen QDimopoulos NLuke TMurphy RScott AMMaraskovsky EMcArthur GMacGregor DSturrock STai TYGreen SCuthbertson AMaher DMiloradovic LMitchell SVRitter GJungbluth AAChen YTGnjatic SHoffman EWOld LJCebon JS. errata for Davis et al., Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans, PNAS 2004 101:10697-10702.
Proceedings of the National Academy of Sciences of USA.
102:9734-9734.
2005
Full text if available -
Rigopoulos ALee FTScott AM. A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake.
Clinical Cancer Research.
11:4810-4817.
2005
Full text if available -
Harris MTBerlangieri SUCebon JSDavis IDScott AM. Impact of 2-Deoxy-2[F-18]Fluoro-d-Glucose Positron Emission Tomography on the Management of Patients with Advanced Melanoma.
Molecular Imaging and Biology.
7:304-308.
2005
Full text if available -
Scott ALee FTChong G. Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma.
Clinical Cancer Research.
11:4818-4826.
2005
Full text if available -
Murphy RGreen SRitter GCohen LRyan DWoods WRubira MCebon JDavis IDSjolander AKypridis AKalnins HMcNamara MMoloney MBAckland JCartwright GRood JDumsday GHealey KMaher DMaraskovsky EChen YHoffman EWOld LJScott AM. Recombinant NY‐ESO‐1 Cancer Antigen: Production and Purification under cGMP Conditions.
Preparative Biochemistry and Biotechnology.
35:119-134.
2005
Full text if available -
Ackermann UTochon-Danguy HJNerrie MNice ECSachinidis JIScott AM. Synthesis, 11C labeling and biological properties of derivatives of the tyrphostin AG957.
Nuclear Medicine and Biology.
32:323-328.
2005
Full text if available -
Johns TGMellman ICartwright GARitter GOld LJBurgess AWScott AM. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.
The FASEB Journal.
19:780-782.
2005
Full text if available -
Panousis CRayzman VMJohns TGRenner CLiu ZCartwright GLee F-TWang DGan HCao DKypridis ASmyth FEBrechbiel MWBurgess AWOld LJScott AM. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.
British Journal of Cancer.
92:1069-1077.
2005
Full text if available -
Putra LJLawrentschuk NBallok ZHannah APoon ATauro ADavis IDHicks RJBolton DMScott AM. Erratum.
Urology.
65:632-632.
2005
Full text if available -
Scott AMLiu ZMurone CJohns TGMacGregor DSmyth FELee FTCebon JDavis IDHopkins WMountain AJRigopoulos AHanai NOld LJ. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.
Cancer Immunity.
5.
2005
-
Johns Putra LLawrentschuk NBallok ZHannah APoon ATauro ADavis IDHicks RJBolton DMScott AM. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
Urology.
64:1202-1207.
2004
Full text if available -
FOO SABBOTT DLAWRENTSCHUK NSCOTT A. Functional imaging of intratumoral hypoxia.
Molecular Imaging and Biology.
6:291-305.
2004
Full text if available -
Issa WTochon-Danguy HJLambert JSachinidis JIAckermann ULiu ZScott AM. Synthesis and evaluation of a thymidine analog for positron emission tomography study of tumor DNA proliferation in vivo.
Nuclear Medicine and Biology.
31:839-849.
2004
Full text if available -
Luwor RBZhu H-JWalker FVitali AAPerera RMBurgess AWScott AMJohns TG. The tumor-specific de2–7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.
Oncogene.
23:6095-6104.
2004
Full text if available -
Davis IDChen WJackson HParente PShackleton MHopkins WChen QDimopoulos NLuke TMurphy RScott AMMaraskovsky EMcArthur GMacGregor DSturrock STai TYGreen SCuthbertson AMaher DMiloradovic LMitchell SVRitter GJungbluth AAChen Y-TGnjatic SHoffman EWOld LJCebon JS. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans.
Proceedings of the National Academy of Sciences of USA.
101:10697-10702.
2004
Full text if available -
Johns TGAdams TECochran JRHall NEHoyne PAOlsen MJKim Y-SRothacker JNice ECWalker FRitter GJungbluth AAOld LJWard CWBurgess AWWittrup KDScott AM. Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor.
Journal of Biological Chemistry.
279:30375-30384.
2004
Full text if available -
Ackermann UTochon-Danguy HJScott AM. BF3 etherate catalysed formation of[11C]methyl esters: a novel radiolabelling technique.
Journal of Labelled Compounds and Radiopharmaceuticals.
47:523-530.
2004
Full text if available -
Foo SSMitchell PLBerlangieri SUSmith CLScott AM. Positron emission tomography scanning in the assessment of patients with lymphoma.
Internal Medicine Journal.
34:388-397.
2004
Full text if available -
Ramsland PAFarrugia WBradford TMMark Hogarth PScott AM. Structural Convergence of Antibody Binding of Carbohydrate Determinants in Lewis Y Tumor Antigens.
Journal of Molecular Biology.
340:809-818.
2004
Full text if available -
Foo SSRamdave SBerlangieri SUScott AM. Detection of occult bone metastases of lung cancer with Fluorine-18 fluorodeoxyglucose positron emission tomography.
Journal of Medical Imaging and Radiation Oncology.
48:214-216.
2004
Full text if available -
Walker FOrchard SGJorissen RNHall NEZhang H-HHoyne PAAdams TEJohns TGWard CGarrett TPJZhu H-JNerrie MScott AMNice ECBurgess AW. CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor.
Journal of Biological Chemistry.
279:22387-22398.
2004
Full text if available -
Bauer SAdrian NWilliamson BPanousis CFadle NSmerd JFettah IScott AMPfreundschuh MRenner C. Targeted Bioactivity of Membrane-Anchored TNF by an Antibody-Derived TNF Fusion Protein.
Journal of Immunology.
172:3930-3939.
2004
Full text if available -
Kloft CGraefe E-UTanswell PScott AMHofheinz RAmelsberg AKarlsson MO. Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients.
Investigational New Drugs.
22:39-52.
2004
Full text if available -
Johns TGLuwor RBMurone CWalker FWeinstock JVitali AAPerera RMJungbluth AAStockert EOld LJNice ECBurgess AWScott AM. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
Proceedings of the National Academy of Sciences of USA.
100:15871-15876.
2003
Full text if available -
Tahtis KLee FTWheatley JMGarin-Chesa PPark JESmyth FEObata YStockert EHall CMOld LJRettig WJScott AM. Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.
Molecular Cancer Therapeutics.
2:729-737.
2003
-
Liu ZPanousis CSmyth FEMurphy RWirth VCartwright GJohns TGScott AM. Generation of Anti-Idiotype Antibodies for Application in Clinical Immunotherapy Laboratory Analyses.
Hybridoma: a journal of molecular immunology and experimental and clinical immunotherapy.
22:219-228.
2003
Full text if available -
Lee FTScott AM. Immuno-PET for tumor targeting.
Journal of Nuclear Medicine.
44:1282-1283.
2003
-
Mitchell PLee FTHall CRigopoulos ASmyth FEHekman AMVan Schijndel GMPowles RBrechbiel MWScott AM. Targeting primary human Ph+ B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.
Journal of Nuclear Medicine.
44:1105-1112.
2003
-
Scott AMWiseman GWelt SAdjei ALee FTHopkins WDivgi CRHanson LHMitchell PGansen DNLarson SMIngle JNHoffman EWTanswell PRitter GCohen LSBette PArvay LAmelsberg AVlock DRettig WJOld LJ. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Clinical Cancer Research.
9:1639-1647.
2003
-
Scott APower BE. Noncovalent scFv multimers of tumor-targeting anti-Lewisy hu3S193 humanized antibody.
Protein Science.
12:734-747.
2003
Full text if available -
Jungbluth AAStockert ESu Huang HJCollins VPCoplan KIversen KKolb DJohns TJScott AMGullick WJRitter GCohen LScanlan MJCavenee WKOld LJ. Erratum: A monoclonal antibody recognizing human cancers with amplifications/overexpression of the human epidermal growth factor receptor (Proceedings of the National Academy of Sciences of the United States of America (January 21, 2003) 100:2 (639-644)).
Proceedings of the National Academy of Sciences of USA.
100:2163.
2003
-
Froomes PRSachinidis JGhabrial HTochon-Danguy HScott AChing MSMorgan DJAngus PW. A novel method for determining hepatic sinusoidal oxygen permeability in the isolated perfused rat liver using [15O]O2.
Nuclear Medicine and Biology.
30:93-100.
2003
Full text if available -
Jungbluth AAStockert EHuang HJSCollins VPCoplan KIversen KKolb DJohns TJScott AMGullick WJRitter GCohen LScanlan MJCavanee WKOld LJ. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.
Proceedings of the National Academy of Sciences of USA.
100:639-644.
2003
Full text if available -
Liu ZLee FTHanai NSmyth FEBurgess AWOld LJScott AM. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicitymediated by chimeric anti-GD3 monoclonal antibody KM871.
Cancer Immunity.
5:1-14.
2002
-
Scott ACasse R. Positron Emission Tomography and Epilepsy.
Molecular Imaging and Biology.
4:338-351.
2002
Full text if available -
Hannah AScott AMTochon-Danguy HChan JGAkhurst TBerlangieri SPrice DSmith GJSchelleman TMcKay WJSizeland A. Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Histopathologic Correlation in the Initial Staging of Head and Neck Cancer.
Annals of Surgery.
236:208-217.
2002
Full text if available -
Markus RDonnan GAKazui SRead SHirano TScott AMO'Keefe GJTochon-Danguy HJSachinidis JIReutens DC. Statistical Parametric Mapping of Hypoxic Tissue Identified by [18F]Fluoromisonidazole and Positron Emission Tomography Following Acute Ischemic Stroke.
Neuroimage.
16:425-433.
2002
Full text if available -
Scott ALee FTLiu, Fiona E. Smyth, Christoph Renn Z. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
Cancer Immunology Immunotherapy.
51:171-177.
2002
Full text if available -
Johns TGStockert ERitter GJungbluth AAHuang H-JSCavenee WKSmyth FEHall CMWatson NNice ECGullick WJOld LJBurgess AWScott AM. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
International Journal of Cancer.
98:398-408.
2002
Full text if available -
Ackermann UTochon-Danguy HJYoung KSachinidis JIGordon Chan JScott AM. 11C labelling of AG957?a potential tyrphostin radiotracer for PET.
Journal of Labelled Compounds and Radiopharmaceuticals.
45:157-165.
2002
Full text if available -
Tochon-Danguy HJSachinidis JIChan FGordon Chan JHall CCher LStylli SHill JKaye AScott AM. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [ 18 F]fluoromisonidazole (FMISO).
Nuclear Medicine and Biology.
29:191-197.
2002
Full text if available -
Liu ZLee FTHanai NSmyth FEBurgess AWOld LJScott AM. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871..
Cancer Immunity.
2:13.
2002
-
Rayzman VMScott AM. Monoclonal antibodies for cancer therapy.
Cancer Forum.
26:104-108.
2002
-
Scott ABrown IBoots RBowman RMcEvoy DMorrison S. Haemoptysis in the adult under 40 - a clinico-pathological review.
Respirology.
6.
2001
-
Gallicchio MAKneen MHall CScott AMBach LA. Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growthin vivo.
International Journal of Cancer.
94:645-651.
2001
Full text if available -
Scott AMLee F-THopkins WCebon JSWheatley JMLiu ZSmyth FEMurone CSturrock SMacGregor DHanai NInoue KYamasaki MBrechbiel MWDavis IDMurphy RHannah ALim-Joon MChan TChong GRitter GHoffman EWBurgess AWOld LJ. Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial.
Journal of Clinical Oncology.
19:3976-3987.
2001
Full text if available -
RAMDAVE SHAKHERTHOMAS GWYNNEWBERLANGIERI SALVATOREUBOLTON DAMIENMDAVIS IANDANGUY H-TMACGREGOR DUNCANSCOTT ANDREWM. CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA.
Journal of Urology.
166:825-830.
2001
Full text if available -
Barendswaard ECHumm JLO'Donoghue JASgouros GFinn RDScott AMLarson SMWelt S. Relative therapeutic efficacy of 125I- and 131I-labeled monoclonal antibody A33 in a human colon cancer xenograft.
Journal of Nuclear Medicine.
42:1251-1256.
2001
-
Mishima KJohns TGLuwor RBScott AMStockert EJungbluth AAJi XDSuvarna PVoland JROld LJSu Huang HJCavenee WK. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Cancer Research.
61:5349-5354.
2001
-
Luwor RBJohns TGMurone CSu Huang HJCavenee WKRitter GOld LJBurgess AWScott AM. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Cancer Research.
61:5355-5361.
2001
-
Power BECaine JMBurns JEShapira DRHattarki MKTahtis KLee F-TSmyth FEScott AMKortt AAHudson PJ. Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector.
Cancer Immunology Immunotherapy.
50:241-250.
2001
Full text if available -
Lee FTRigopoulos AHall CClarke KCody SHSmyth FELiu ZBrechbiel MWHanai NNice ECCatimel BBurgess AWWelt SRitter GOld LJScott AM. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G
D3 ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Research. 61:4474-4482. 2001
-
Lee FTHall CRigopoulos AZweit JPathmaraj KO'Keefe GJSmyth FEWelt SOld LJScott AM. Immuno-PET of human colon xenograft-bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.
Journal of Nuclear Medicine.
42:764-769.
2001
-
Renner CStehle ILee FTHall CCatimel BNice ECMountain ARigopoulos ABrechbiel MWPfreundschuh MScott AM. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
Cancer Immunology Immunotherapy.
50:102-108.
2001
Full text if available -
Scott AM. Current status of positron emission tomography in oncology.
Internal Medicine Journal.
31:27-36.
2001
Full text if available -
Tanswell PGarin-Chesa PRettig WJWelt SDivgi CRCasper ESFinn RDLarson SMOld LJScott AM. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.
British Journal of Clinical Pharmacology.
51:177-180.
2001
Full text if available -
Tahtis KLee FTSmyth FEPower BERenner CBrechbiel MWOld LJHudson PJScott AM. Biodistribution properties of 111indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab′)
2 constructs in a breast carcinoma xenograft model. Clinical Cancer Research. 7:1061-1072. 2001
-
Scott A. Overview.
Cancer Forum.
24:210.
2000
-
Berlangieri SScott A. PET in clinical oncology.
Cancer Forum.
24:219-222.
2000
-
Clarke KLee FTBrechbiel MWSmyth FEOld LJScott AM. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: Enhanced activity when combined with taxol chemotherapy.
Clinical Cancer Research.
6:3621-3628.
2000
-
Clarke KLee FTBrechbiel MWSmyth FEOld LJScott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3s193) in MCF-7 xenografted BALB/c nude mice.
Cancer Research.
60:4804-4811.
2000
-
Read SJHirano TAbbott DFMarkus RSachinidis JITochon-Danguy HJChan JGEgan GFScott AMBladin CFMcKay WJDonnan GA. The fate of hypoxic tissue on18F-fluoromisonidazole positron emission tomography after ischemic stroke.
Annals of Neurology.
48:228-235.
2000
Full text if available -
Berlangieri SUScott AM. Metabolic Staging of Lung Cancer.
New England Journal of Medicine.
343:290-292.
2000
Full text if available -
Scott AMGeleick DRubira MClarke KNice ECSmyth FEStockert ERichards ECCarr FJHarris WJArmour KLRood JKypridis AKronina VMurphy RLee FTLiu ZKitamura KRitter GLaughton KHoffman EBurgess AWOld LJ. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
Cancer Research.
60:3254-3261.
2000
-
Achen MGRoufail SDomagala TCatimel BNice ECGeleick DMMurphy RScott AMCaesar CMakinen TAlitalo KStacker SA. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3.
The Federation of European Biochemical Societies (FEBS) Journal.
267:2505-2515.
2000
Full text if available -
Hannah AFeigen MQuong GAkhurst TIMBerlangieri SUZimet AZalcberg JMckay WJScott AM. Use of [18F]-fluorodeoxyglucose positron emission tomography in monitoring response of recurrent neurotropic desmoplastic melanoma to radiotherapy.
Otolaryngology.
122:304-306.
2000
Full text if available -
Scott ABennett EJ. Psychological and sex features of delayed gut transit in functional gastrointestinal disorders.
Gut.
46:83-87.
2000
Full text if available -
Thomas DLRowe CChan JGYoung KBerlangieri SNewton MCasse RScott AM. Stabilised vs standard 99mTc HMPAO for the localisation of epileptic foci using ictal injection - A comparison.
Australian and New Zealand Nuclear Medicine.
31:96-99.
2000
-
Hirano TRead SJAbbott DFSachinidis JITochon-Danguy HJEgan GFBladin CFScott AMMcKay WJDonnan GA. No evidence of hypoxic tissue on 18F-fluoromisonidazole PET after intracerebral hemorrhage.
Neurology.
53:2179-2179.
1999
Full text if available -
Tochon-Danguy HJSachinidis JIEgan GFChan JGBerlangieri SUMcKay WJScott AM. Positron emission tomography: Radioisotope and radiopharmaceutical production.
Australasian Physical and Engineering Sciences in Medicine.
22:136-144.
1999
-
Houlihan CJenkins MOsicka TScott AParkin DJerums G. A comparison of the plasma disappearance of iohexol and 99m Tc-DTPA for the measurement of glomerular filtration rate (GFR) in diabetes.
Australian and New Zealand Journal of Medicine.
29:693-700.
1999
Full text if available -
POINTON OWENSCOTT ANDREWMBERLANGIERI SALVATOREMcKAY WJOHNGOLDSTEIN DAVID. F-18 Fluorodeoxyglucose PET and Ga-67 Citrate Scintigraphy in a Case of AIDS Lymphoma and Pericarditis.
Clinical Nuclear Medicine.
24:817-817.
1999
Full text if available -
Hanna AU PWallace ASchleyer PLee FTJones RHopkins WMacGregor DCebon JRigopoulos AThomas DMcKay WJWelt SRichards EKolbert KSSgouros GOld LBurgess AWScott AM. Phase I study of humanised antibody A33 (Hua33) in patients with colorectal carcinoma - Preliminary whole body clearance and tumour dosimetry: Short title: Dosimetric analysis of [I-131]huA33.
Australian and New Zealand Nuclear Medicine.
30:52-55.
1999
-
Scott AReutens D. Clinical Applications of [15O] H2O PET Activation Studies.
Molecular Imaging and Biology.
2:145-152.
1999
Full text if available -
Scott AM. Positron emission tomography In assessing response to neoadjuvant chemotherapy for non‐small‐cell lung cancer: In reply.
Medical Journal of Australia.
170:237-237.
1999
Full text if available -
Read SJHirano TAbbott DFSachinidis JITochon-Danguy HJChan JGEgan GFScott AMBladin CFMcKay WJDonnan GA. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole.
Neurology.
51:1617-1621.
1998
Full text if available -
Divgi CRBander NHScott AMO'Donoghue JASgouros GWelt SFinn RDMorrissey FCapitelli PWilliams JMDeland DNakhre AOosterwijk EGulec SGraham MCLarson SMOld LJ. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
Clinical Cancer Research.
4:2729-2739.
1998
-
Thomas DMMitchell PLRBerlangieri SUTochon-Danguy HKnight SClarke CPScott AM. Correction: Positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer (Medical Journal of Australia (1998) 169 (227)).
Medical Journal of Australia.
169:344.
1998
-
Catimel BScott AMLee FTHanai NRitter GWelt SOld LJBurgess AWNice EC. Direct immobilization of gangliosides onto gold-carboxymethyldextran sensor surfaces by hydrophobic interaction: applications to antibody characterization.
Glycobiology.
8:927-938.
1998
Full text if available -
Thomas DMMitchell PLRBerlangleri SUTochon‐Danguy HKnight SClarke CPScott AM. Positron emission tomography In assessing response to neoadjuvant chemotherapy for non‐small‐cell lung cancer.
Medical Journal of Australia.
169:227-227.
1998
Full text if available -
Kiffer JDBerlangieri SUScott AMQuong GFeigen MSchumer WClarke CPKnight SRDaniel FJ. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer1Presented at the 13th Asia Pacific Cancer Conference, Penang, Malaysia, November 17–20, 1996 and also presented at the Royal Australasian College of Radiologists 47th Annual General and Scientific Meeting, Perth, Western Australia, October 5–9th, 1996. Accepted for presentation at the American Radium Society 79th Annual Meeting, New York, N.Y., April 30–May 4, 1997.1.
Lung Cancer.
19:167-177.
1998
Full text if available -
Barendswaard ECScott AMDivgi CRWilliams CCoplan KRiedel EYao TJGansow OAFinn RDLarson SMOld LJWelt S. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice..
International Journal of Oncology.
12:45-53.
1998
Full text if available -
Nicholson ICLenton KALittle DJDecorso TLee FTScott AMZola HHohmann AW. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma.
Molecular Immunology.
34:1157-1165.
1997
Full text if available -
Scott AMWelt S. Antibody-based immunological therapies.
Current Opinion in Immunology.
9:717-722.
1997
Full text if available -
Scott AMCebon J. Clinical promise of tumour immunology.
Lancet.
349:S19-S22.
1997
Full text if available -
Cebon JMacgregor DScott ADeboer R. Immunotherapy of melanoma: Targeting defined antigens.
Australasian Journal of Dermatology.
38:S66-S72.
1997
Full text if available -
Kolbert KSSgouros GScott AMBronstein JEMalane RAZhang JKalaigian HMcNamara SSchwartz LLarson SM. Implementation and evaluation of patient-specific three-dimensional internal dosimetry.
Journal of Nuclear Medicine.
38:301-308.
1997
-
Heath JKWhite SJJohnstone CNCatimel BSimpson RJMoritz RLTu G-FJi HWhitehead RHGroenen LCScott AMRitter GCohen LWelt SOld LJNice ECBurgess AW. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily.
Proceedings of the National Academy of Sciences of USA.
94:469-474.
1997
Full text if available -
Roach PJHansen PSScott AMCooper RAHoschl RWiseman JCBernar AEdwards AC. Comparison of optimised planar scintigraphy with SPECT thallium, exercise ECG and angiography in the detection of coronary artery disease.
Australian and New Zealand Journal of Medicine.
26:806-812.
1996
Full text if available -
Catimel BRitter GWelt SOld LJCohen LNerrie MAWhite SJHeath JKDemediuk BDomagala TLee FTScott AMTu GFJi HMoritz RLSimpson RJBurgess AWNice EC. Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium.
Journal of Biological Chemistry.
271:25664-25670.
1996
Full text if available -
Hannah AScott AMAkhurst TBerlangieri SBishop JMcKay WJ. Abnormal colonic accumulation of fluorine-18-FDG in pseudomembranous colitis.
Journal of Nuclear Medicine.
37:1683-1685.
1996
-
Welt SScott AMDivgi CRKemeny NEFinn RDDaghighian FGermain JSRichards ECLarson SMOld LJ. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer..
Journal of Clinical Oncology.
14:1787-1797.
1996
Full text if available -
Sgouros GJureidini IMScott AMGraham MCLarson SMScheinberg DA. Bone Marrow Dosimetry: Regional Variability of Marrow-Localizing Antibody.
Journal of Nuclear Medicine.
37:695-698.
1996
-
Burt MScott AWilliard WCPommier RYeh SBains MSTurnbull ADFortner JGMcCormack PMGinsberg RJ. Erythromycin stimulates gastric emptying after esophagectomy with gastric replacement: A randomized clinical trial.
Journal of Thoracic and Cardiovascular Surgery.
111:649-654.
1996
Full text if available -
Daghighian FBarendswaard EWelt SHumm JScott AWillingham MCMcGuffie EOld LJLarson SM. Enhancement of Radiation Dose to the Nucleus by Vesicular Internalization of Iodine-125-Labeled A33 Monoclonal Antibody.
Journal of Nuclear Medicine.
37:1052-1057.
1996
-
Abdel-Dayem HMScott AMacapinlac HLarson S. Tracer imaging in lung cancer.
European Journal of Nuclear Medicine and Molecular Imaging.
22:1355-1355.
1995
Full text if available -
Divgi CRScott AMGulec SBroussard EKLevy NYoung CCapitelli PDaghighian FWilliams JMFinn RDKemeny NHilton SKelsen DMilenic DELora MESchlom JLarson SM. Pilot Radioimmunotherapy Trial with 131I-labeled Murine Monoclonal Antibody CC49 and Deoxyspergualin in Metastatic Colon Carcinoma.
Clinical Cancer Research.
1:1503-1510.
1995
-
Scott AMRosa EMehta BMDivgi CRFinn RDBiedler JLTsuruo TKalaigian HLarson SM. In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody.
Nuclear Medicine and Biology.
22:497-504.
1995
Full text if available -
Ugur OScott AMKostakoglu LHui TEMasterson MEFebo RSgouros GRosa EMehta BMFisher DRCheung N-KVLarson SM. Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.
Nuclear Medicine and Biology.
22:87-93.
1995
Full text if available -
CALUSER CALINSCOTT ANDREWMACAPINLAC HOMERYEH SAMUELROSENFELT NANCYFARID BOULADABDEL-DAYEM HUSSEINMLARSON STEVENMKALAIGIAN HOVANES. Extramedullary Hematopoiesis Assessment in a Patient With Osteopetrosis.
Clinical Nuclear Medicine.
20:75-75.
1995
Full text if available -
Scott AMMacapinlac HZhang JDaghighian FMontemayor NKalaigian HSgouros GGraham MCKolbert KYeh SDJLai EGoldsmith SJLarson SM. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer.
Journal of Nuclear Medicine.
36:100-103.
1995
-
Divgi CRScott AMDantis LCapitelli PSiler KHilton SFinn RDKemeny NKelsen DKostakoglu LSchlom JLarson SM. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
Journal of Nuclear Medicine.
36:586-592.
1995
-
Schneider JADivgi CRScott AMMacapinlac HASeidman ADGoldsmith SJLarson SM. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer.
Journal of Nuclear Medicine.
35:1748-1752.
1994
-
Caluser CAbdel-Dayem HMacapinlac HScott AHealey JHuvos AKalaigian HYeh SJLarson S. The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas.
European Journal of Nuclear Medicine and Molecular Imaging.
21:1198-1205.
1994
Full text if available -
Welt SDivgi CRKemeny NFinn RDScott AMGraham MGermain JSRichards ECLarson SMOettgen HF. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer..
Journal of Clinical Oncology.
12:1561-1571.
1994
Full text if available -
Scott AMMacapinlac HZhang JJKalaigian HGraham MCDivgi CRSgouros GGoldsmith SJLarson SM. Clinical applications of fusion imaging in oncology.
Nuclear Medicine and Biology.
21:775-784.
1994
Full text if available -
Larson SMDivgi CScott ADaghighian FMacapinlac HWelt S. Current status of radioimmunodetection.
Nuclear Medicine and Biology.
21:721-729.
1994
Full text if available -
Larson SMDivgi CRScott ASgouros GGraham MCKostakoglu LScheinberg DCheung N-KVSchlom JFinn RD. Current status of radioimmunotherapy.
Nuclear Medicine and Biology.
21:785-792.
1994
Full text if available -
Macapinlac HAScott AMLarson SMDivgi CRYeh SDJGoldsmith SJ. Gallium-67-citrate imaging in nuclear oncology.
Nuclear Medicine and Biology.
21:731-738.
1994
Full text if available -
Welt SDivgi CRScott AMGarin-Chesa PFinn RDGraham MCarswell EACohen ALarson SMOld LJ. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts..
Journal of Clinical Oncology.
12:1193-1203.
1994
Full text if available -
Tennant CMihailidou AScott ASmith RKellow JJones MHunyor SLorang MHoschl R. Psychological symptom profiles in patients with chest pain.
Journal of Psychosomatic Research.
38:365-371.
1994
Full text if available -
Caron PCJurcic JGScott AMFinn RDDivgi CRGraham MCJureidini IMSgouros GTyson DOld LJLarson SMScheinberg DA. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity.
Blood.
83:1760-1768.
1994
-
Larson SMDivgi CRScott AM. Overview of clinical radioimmunodetection of human tumors.
Cancer.
73:832-835.
1994
Full text if available -
Divgi CRScott AMMcDermott KFallone PSHilton SSiler KCarmichael NDaghighian FFinn RDCohen AMSchlom JLarson SM. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen.
Nuclear Medicine and Biology.
21:9-15.
1994
Full text if available -
Scott AMMacapinlac HADivgi CRZhang JJKalaigian HPentlow KHilton SGraham MCSgouros GPelizzari CChen GSchlom JGoldsmith SJLarson SM. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma.
Journal of Nuclear Medicine.
35:1976-1984.
1994
-
Tjuvajev JGMacapinlac HADaghighian FScott AMGinos JZFinn RDKothari PDesai RZhang JBeattie BGraham MLarson SMBlasberg RG. Imaging of brain tumor proliferative activity with iodine-131- iododeoxyuridine.
Journal of Nuclear Medicine.
35:1407-1417.
1994
-
SCOTT AMBERLANGIERI SU. POSITRON EMISSION TOMOGRAPHY IN COLORECTAL-CARCINOMA.
DIAGNOSTIC ONCOLOGY.
4:123-129.
1994
-
Kostakoglu LDivgi CRHilton SCordon-Cardo CScott AMKalaigian HFinn RDSchlom JLarson SM. Preselection of Patients with High TAG-72 Antigen Expression Leads to Targeting of 94% of Known Metastatic Tumor Sites with Monoclonal Antibody I-131-CC49.
Cancer Investigation.
12:551-558.
1994
Full text if available -
SCOTT AMLARSON SMDIVGI CRWELT S. RADIOIMMUNODETECTION OF COLORECTAL-CANCER.
DIAGNOSTIC ONCOLOGY.
4:115-122.
1994
-
Abdel-Dayem HScott AMacapinlac HLarson S. Tracer imaging in lung cancer.
European Journal of Nuclear Medicine and Molecular Imaging.
21:57-81.
1994
Full text if available -
Scott AMKellow JEShuter BCowan HCorbett A-MRiley JWLunzer MREckstein RPH�schl RLam S-KJones MP. Intragastric distribution and gastric emptying of solids and liquids in functional dyspepsia.
Digestive Diseases and Sciences.
38:2247-2254.
1993
Full text if available -
SCHNEIDER JADIVGI CRSCOTT AMMACAPINLAC HASONENBERG MGOLDSMITH SJLARSON SM. Hiatal Hernia on Whole-Body Radioiodine Survey Mimicking Metastatic Thyroid Cancer.
Clinical Nuclear Medicine.
18:751-753.
1993
Full text if available -
Preston SJDiamond TScott ALaurent MR. Methotrexate osteopathy in rheumatic disease..
Annals of the Rheumatic Diseases.
52:582-585.
1993
Full text if available -
Scott AMKellow JEShuter BNolan JMHoschl RJones MP. Effects of cigarette smoking on solid and liquid intragastric distribution and gastric emptying.
Gastroenterology.
104:410-416.
1993
Full text if available -
Scott AMihailidou ASmith RKellow JJones MLorang CHunyor SLorang MHoschl RTennant C. Functional Gastrointestinal Disorders in Unselected Patients with Non-Cardiac Chest Pain.
Scandinavian Journal of Gastroenterology.
28:585-590.
1993
Full text if available -
Divgi CRMcDermott KGriffin TWJohnson DKSchnobrich KEFallone PSScott AMHilton SCohen AMLarson SM. Lesion-by-lesion comparison of computerized tomography and indium-111- labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: A multicenter trial.
Journal of Nuclear Medicine.
34:1656-1661.
1993
-
Larson SMMacapinlac HAScott AMDivgi CR. Recent Achievements in the Development of Radiolabeled Monoclonal Antibodies for Diagnosis, Therapy and Biologic Characterization of Human Tumors.
Acta Oncologica.
32:709-715.
1993
Full text if available -
Scott AMLarson SM. Tumor imaging and therapy.
Radiologic Clinics of North America.
31:859-880.
1993
-
Scott AMKellow JEEckersley GMNolan JMJones MP. Cigarette smoking and nicotine delay postprandial mouth-cecum transit time.
Digestive Diseases and Sciences.
37:1544-1547.
1992
Full text if available -
Scott AMKostakoglu LO'Brien JPStraus DJAbdel-Dayem HMLarson SM. Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma.
Journal of Nuclear Medicine.
33:1396-1398.
1992
-
Bennett EJKellow JECowan HScott AMShuter BLangeluddecke PMHoschl RJones MPTennant CC. Suppression of Anger and Gastric Emptying in Patients with Functional Dyspepsia.
Scandinavian Journal of Gastroenterology.
27:869-874.
1992
Full text if available
-
Parakh SKing DGan HKScott AM. Current Development of Monoclonal Antibodies in Cancer Therapy.
Recent Results in Cancer Research.
214:1-70.
2020
-
case study
-
Tan GJSLee STBerlangieri SUScott AM. Periarticular FDG uptake on PET/CT in malignant melanoma-metastatic or misleading?.
Annals of the Academy of Medicine, Singapore.
159-160.
2013
-
Tan GJSLee STBerlangieri SUScott AM. Periarticular FDG uptake on PET/CT in malignant melanoma-metastatic or misleading?.
Annals of the Academy of Medicine, Singapore.
159-160.
2013
-
chapter
-
Scott AMCiprotti MLee ST. Diagnostic Applications of Nuclear Medicine: Malignant Melanoma.
1065-1102.
2017
Full text if available -
Scott AMCiprotti MLee ST. Malignant melanoma..
635-661.
2013
Full text if available -
Agostino MFarrugia WSandrin MSScott AMYuriev ERamsland PA. Structural glycobiology of antibody recognition in xenotransplantation and cancer immunotherapy.
203-228.
2012
Full text if available -
Burvenich IScott A. The Delivery Construct: Maximizing the Therapeutic Ratio of Targeted Radionuclide Therapy.
236-248.
2010
-
Scott AMLee S-T. Clinical Radionuclide Therapy.
349-385.
2008
Full text if available
-
Scott AMCiprotti MLee ST. Diagnostic Applications of Nuclear Medicine: Malignant Melanoma.
1065-1102.
2017
-
comment
-
Bodei LChiti AModlin IMScott AMSchöder H. The path to the future: Education of nuclear medicine therapeutic specialists as responsible physicians.
Journal of Nuclear Medicine.
1663-1664.
2019
Full text if available -
Bailey DLHofman MSForwood NJO'Keefe GScott AMvan Wyngaardt WMHowe BKovacev OFrancis RJ. Accuracy of Dose Calibrators for 68 Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment.
Journal of Nuclear Medicine.
636-638.
2018
Full text if available
-
Bodei LChiti AModlin IMScott AMSchöder H. The path to the future: Education of nuclear medicine therapeutic specialists as responsible physicians.
Journal of Nuclear Medicine.
1663-1664.
2019
-
conference paper
-
Scott A. 2019 SNMMI Highlights Lecture: Oncology and Therapy.
Journal of Nuclear Medicine.
11N-17N.
2020
-
Gan HCher LInglis PLwin ZLau EWichmann CAckermann UCoombs NRemen KGuo NLee STGong SPalmer JBPathmaraj KO'Keefe GScott FDay BWBoyd AWThomas PDurrant CScott AM. Abstract CT063: Preliminary findings of a Phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma.
Cancer Research.
2019
Full text if available -
Chia PLCao DGan HKReilly EBPhillips AJohn TScott AM. ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo..
Journal of Clinical Oncology.
e14677-e14677.
2019
Full text if available -
Wichmann CAckermann UPoniger SYoung KChan JHofman MSachinidis JScott A. Automated radiosynthesis of [Lu-177] Lu-PSMA-617 on the iPHASE MultiSyn module.
Journal of Labelled Compounds and Radiopharmaceuticals.
S329-S329.
2019
-
Harding EWelch JTesta CPathmaraj KLee STScott A. IMPACT OF THE BONE SCAN IN A COMPLICATED MENINGOCOCCAL PATIENT.
Internal Medicine Journal.
36-36.
2019
-
Saunus JMLim MPuttick SKalita-de Croft PHouston ZHJones MLLatter MJCampbell LCThomas PJeffree RLRose SEMahler SMThurecht KJScott AMLakhani SR. Abstract P1-19-02: Innovation in diagnosis and treatment of brain metastases using multifunctional nanomedicines.
Cancer Research.
2019
Full text if available -
Nguyen MPathmaraj KLee SMorigi JScott A. Artificial intelligence vs human intelligence: quotient analysis on lung VQ scan for diagnosis of pulmonary embolism.
Internal Medicine Journal.
38-38.
2019
Full text if available -
Wichmann CAckermann UPoniger SYoung KChan GHofman MLee SSachinidis JScott A. Automated radiosynthesis of [177Lu]Lu‐PSMA‐617 on the iPHASE MultiSyn module.
Internal Medicine Journal.
31-32.
2019
Full text if available -
Chen TMaloney JLee SLau EBerlangieri SScott ABarnett S. Correlation of metabolic parameters on 18F‐FDG PET with recurrence in patients with resected lung metastases from colorectal carcinoma.
Internal Medicine Journal.
7-7.
2019
Full text if available -
McDonald AGoh YWWhite JMScott AAckermann U. Investigation of automated radiofluorination methods for oxidatively sensitive aryl systems.
European Journal of Nuclear Medicine and Molecular Imaging.
S725-S726.
2019
-
Metser UChua SHo NBBPunwani SJohnston EPouliot FTau NHawsawy AAnconina RBauman GHicks RWeickhardt ADavis IPond GScott AEmmett L. The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy..
Journal of Nuclear Medicine.
2019
-
Owen CPoon ALee SMcMaster CPathmaraj KScott ABuchanan R. Volar hand uptake on 18F‐FDG whole body PET/CT predicts glucocorticoid-responsive disease in polymyalgia rheumatica: results from the MPR-PMR study.
Internal Medicine Journal.
20-20.
2019
Full text if available -
Owen CMcMaster CLiew DLeung JScott ABuchanan R. Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica.
Arthritis and Rheumatology.
2018
-
Owen CEPoon AMYap LPLeung JLLiew DFLee STScott AMBuchanan RR. AB0671 First documentation of rs3pe affecting the hands on 18f-fdg whole body pet/ct in polymyalgia rheumatica.
Annals of the Rheumatic Diseases.
1479-1480.
2018
Full text if available -
Owen CEMartin EPoon AMLeung JLLiew DFLee STScott AMBuchanan RR. AB0672 18f-fdg whole body pet/ct as a diagnostic test for polymyalgia rheumatica in patients with normal inflammatory markers.
Annals of the Rheumatic Diseases.
1480-1480.
2018
Full text if available -
Owen CMartin EPoon ALeung JLiew DLee STScott ABuchanan R. 18F-FDG WHOLE BODY PET/CT AS A DIAGNOSTIC TEST FOR POLYMYALGIA RHEUMATICA IN PATIENTS WITH NORMAL INFLAMMATORY MARKERS.
Internal Medicine Journal.
45-45.
2018
-
Owen CPoon AYap LPLeung JLiew DLee STScott ABuchanan R. FIRST DOCUMENTATION OF RS3PE AFFECTING THE HANDS ON 18F-FDG WHOLE BODY PET/CT IN POLYMYALGIA RHEUMATICA.
Internal Medicine Journal.
45-45.
2018
-
Wichmann CParslow AAckermann URigopoulos AScott AMWhite J. Abstracts.
Internal Medicine Journal.
7-19.
2018
Full text if available -
Lee SLee STPoon ABerlangieri SUScott AM. EVALUATION OF CLINICAL RISK FACTORS WHICH MAY PREDICT REGIONAL, NODAL AND METASTATIC DISEASE ON (68)GA-PSMA PET/CT.
Internal Medicine Journal.
14-14.
2018
-
McDonald AParslow AGoh YWWhite JScott AMAckermann U. HARNESSING ANALOGUES OF THE ONCRASIN-1 FOR RADIOTRACER IMAGING OF TARGETED THERAPY RESISTANCE.
Internal Medicine Journal.
12-13.
2018
-
Welch JBerlangieri SUO'Keefe GJPathmaraj KScott A. INVESTIGATING SUITABLE VOXEL SIZE FOR PATIENTS OF VARYING BODY MASS INDEX (BMI) TO ENHANCE IMAGE QUALITY OF PET/CT IMAGES.
Internal Medicine Journal.
17-18.
2018
-
Bauman GSMetser UScott APouliot FWeickhardt ADavis IHicks RPunwani SChua SEmmett L. A Prospective Study of F-18 Fluoro-methyl-choline (FCH) And Ga-68 HBED-CC- (PSMA) in Men being Considered for Salvage Radiation Treatment for Biochemical Failure Post Radical Prostatectomy.
International Journal of Radiation: Oncology - Biology - Physics.
S162-S162.
2018
Full text if available -
Emmett LMetser UBauman GHicks RPouliot FDavis IChua SWeickhardt APunwani SHo BJohnston EScott A. A prospective, multinational comparison of multi-parametric and whole body magnetic resonance imaging (mp-MRI and WB-MRI) F-18 fluoro-methyl-choline (FCH) and Ga-68 HBED-CC-(PSMA) in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy: Detection rates, management impact and treatment response.
Journal of Nuclear Medicine.
2018
-
Chia PLCao DGan HRigopoulos ARiley EPhillips AJohn TScott A. ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo.
Journal of Thoracic Oncology.
S745-S745.
2018
Full text if available -
Chia PLCao DRigopoulos AGan HReilly EPhillips AJohn TScott AM. ABT-806-derived antibody-drug conjugates (ADCs) inhibit growth of malignant mesothelioma in vivo.
Cancer Research.
2018
Full text if available -
Chia PLRussell PAsadi KMurone CWalkiewicz MEriksson UScott AJohn T. Analysis of Angiogenic and Stromal Biomarkers in a Large Malignant Mesothelioma Cohort.
Journal of Thoracic Oncology.
S399-S399.
2018
Full text if available -
Chia PLRussell PMurone CWalkiewicz MEriksson UScott AJohn T. Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort.
Cancer Research.
2018
Full text if available -
Chan JGYoung KAckermann ULivori ATo AVillemange VScott ARowe C. Development of a quality control method for the evaluation of 4-[F-18]fluorobenzyl dexetimide (4-[F-18]FDEX) using high performance liquid chromatography.
Journal of Nuclear Medicine.
2018
-
Parslow AWichmann CRigopoulos AAckermann UWhite JMScott A. Development of small-molecule mTORC1 radiotracers for evaluation of targeted therapy resistance using PET.
Cancer Research.
2018
Full text if available -
Binder ZThorne ABakas SWileyto EPAkbari HRathore SHa SMZhang LIdbaih ABagley SMorrissette JNasrallah MMa JZanca CScott ADavatzikos CFurnari FO'Rourke D. EPIDERMAL GROWTH FACTOR RECEPTOR EXTRACELLULAR DOMAIN MISSENSE MUTATION A289V AS A DRIVER OF GLIOBLASTOMA INVASION AND PROLIFERATION.
Neuro-Oncology.
48-48.
2018
-
Burvenich IJGParakh SLee F-TGuo NLiu ZGan HKRigopoulos AO'Keefe GJGong SJGoh YWTochon-Danguy HScott FEKotsuma MHirotani KSenaldi GScott AM. Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a.
Theranostics.
4199-4209.
2018
Full text if available -
Burvenich IParakh SLee F-TTGuo NYLiu ZGan HRigopoulos AO'Keefe GJGong SJGoh YWScott FKotsuma MHirotani KSenaldi GScott A. PET/MRI with Zr-89-Df-Bz-NCS-Df-DS-5573a as a theranostic approach.
European Journal of Nuclear Medicine and Molecular Imaging.
S639-S640.
2018
Full text if available -
Wichmann CParslow ARigopoulos AAckermann UWhite JMScott A. Preclinical evaluation of a mTOR specific PET ligand in a RAD001 sensitive/resistant breast cancer model system.
European Journal of Nuclear Medicine and Molecular Imaging.
S190-S191.
2018
-
Vargas AKramer GScott AWeickhardt AMeier AParada NBeattie BHumm JStaton KZanzonico PLyashchenko SLewis JYaqub MSosa RWeber WVan den Eertwegh ASchuit RWindhorst AChua SLarson SScher HLammertsma AHoekstra OMorris M. Reproducibility and repeatability of quantitative F-18-fluorodihydrotestosterone (FDHT) uptake metrics in castration resistant prostate cancer metastases: a prospective multi-center study..
Journal of Nuclear Medicine.
2018
-
Morigi JJRajadurai SFerdinandus JWelch JPathmaraj KPoon ABerlangieri SLee STScott AM. The Value of Repeated PET/CT Imaging and Quantitative analysis to define true progression and improve response assessment during Nivolumab treatment: preliminary results from a retrospective, single centre study.
European Journal of Nuclear Medicine and Molecular Imaging.
S236-S237.
2018
-
Lee SLee STPoon ABerlangieri SScott A. The use of Ga-68-PSMA PET scans to evaluate the clinical risk factors predictive of metastatic disease.
Journal of Nuclear Medicine.
2018
-
Thorne AHBinder ZABakas SWileyto EPMorrissette JJDAkbari HRathore SScott ADavatzikos CO'Rourke DFurnari F. EGFR EXTRACELLULAR DOMAIN POINT MUTANT A289V: A THERAPEUTICALLY TARGETABLE DRIVER OF GLIOBLASTOMA INVASION.
Neuro-Oncology.
85-85.
2017
-
Lassman ARoberts-Rapp LHe LLu Xvan den Bent MPapadopoulos KMerrell RKumthekar PReardon DGomez EFischer JJiang FZha ZBhathena AHolen KAnsell PGan HKScott A. MOLECULAR DETERMINANTS ASSOCIATED WITH RESPONSE AND RESISTANCE TO DEPATUXIZUMAB MAFODOTIN (ABT-414) IN PATIENTS WITH RECURRENT GLIOBLASTOMA.
Neuro-Oncology.
176-177.
2017
-
Roach PFrancis REmmett LMcCarthy MScott A. Clinical management intent of Ga68 PSMA PET/CT imaging in prostate cancer: an Australian multicentre study.
Journal of Nuclear Medicine.
2017
-
Gan HKBurge MSolomon BLee STHolen KDZhang YCiprotti MLee FTMerdan TMunasinghe WFischer JDAnsell PFox GXiong HReilly EBHumerickhouse RScott AM. A PHASE 1 AND BIODISTRIBUTION STUDY OF ABT-806I, AN INDIUM-111 RADIOLABELED CONJUGATE OF THE TUMOR-SPECIFIC ANTI-EGFR ANTIBODY ABT-806.
Internal Medicine Journal.
13-13.
2017
-
McArthur SPerera KThapa BNewman MFancourt TLee SJohn TLim ABerlangieri SScott ADavis GKnight SBarnett S. CORRELATION OF METABOLIC PARAMETERS ON 18F-FDG PET WITH PATHOLOGICAL RESPONSE AND OVERALL SURVIVAL IN PATIENTS WITH PANCOAST TUMOURS TREATED WITH TRIMODALITY THERAPY.
Internal Medicine Journal.
6-6.
2017
-
Baker LPathmaraj KLee STScott A. FDG PET/CT SCAN LENDS CLARITY IN MANAGEMENT OF PATIENT DIAGNOSIS.
Internal Medicine Journal.
33-33.
2017
-
Ackermann URigopoulos AJaeger ALO'Keefe GTochon-Danguy HJScott AM. IMAGING OF TG2 ACTIVITY IN BREAST CANCER USING RADIOLABELLED HITOMI PEPTIDES.
Internal Medicine Journal.
11-11.
2017
-
Berlangieri SUPoon ALee STScott AM. IMPLEMENTATION OF A CLINICAL REPORTING QUALITY ASSURANCE PROGRAM IN A HOSPITAL-BASED PET SERVICE.
Internal Medicine Journal.
13-14.
2017
-
Burvenich IParakh SBurvenich JGLee F-TGuo NGan HKRigopoulos AO'Keefe GJGong STochon-Danguy HKotsuma MHirotani KSenaldi GScott AM. MOLECULAR IMAGING OF T-CELL CO-REGULATOR FACTOR B7-H3 WITH 89Zr-DS-5573A.
Internal Medicine Journal.
20-20.
2017
-
Ayati NLee STPoon AMcArthur SAl-Qatawna LPathmaraj KZakavi SRScott AM. SANDOSTATIN LAR THERAPY DIFFERENTIALLY ALTERS Ga-68-DOTATATE UPTAKE IN NORMAL TISSUES AND PRIMARY TUMOURS COMPARED TO METASTATIC LESIONS.
Internal Medicine Journal.
13-13.
2017
-
Tochon-Danguy HJPoniger SSPanopoulos HSachinidis JScott AM. SOLID TARGET PRODUCED ISOTOPES AT AUSTIN HEALTH: 5 YEARS OF EXPERIENCE.
Internal Medicine Journal.
30-30.
2017
-
McArthur SPerera KThapa BNewman MFancourt TLee SBerlangieri SScott AKnight SBarnett S. Association of (18)Fluorodeoxyglucose (FDG), complete pathological response and overall survival in patients with Pancoast tumours treated with trimodality therapy.
European Journal of Nuclear Medicine and Molecular Imaging.
S677-S678.
2017
Full text if available -
Mcarthur SPerera KThapa BNewman MFancourt TLee STJohn TLim ABerlangier SScott ADavis GKnight SBarnett S. Association of FDG PET, Complete Pathological Response and Overall Survival in Patients with Pancoast Tumors Treated with Trimodality Therapy.
Journal of Thoracic Oncology.
S876-S876.
2017
-
Welch JO'Keefe GPathmaraj KScott A. ENHANCING CONTRAST RESOLUTION OF PET/CT IMAGES TO INCREASE LESION DETECTABILITY.
Internal Medicine Journal.
37-38.
2017
-
Ng WWelch JPathmaraj KScott A. IMPLEMENTATION OF MODULATED LOW DOSE CT FOR PET/CT SCANS TO REDUCE RADIATION DOSE TO PATIENT.
Internal Medicine Journal.
33-33.
2017
-
Saleem SPathmaraj KScott AM. NIVOLUMAB INDUCED POLYMYALGIA RHEUMATICA (PMR) FINDINGS IN F-18-FDG PET/CT.
Internal Medicine Journal.
35-35.
2017
-
Mian MOwen CPoon ALee SMcMenamin CLiew DPathmaraj KScott ABuchanan R. SENSITIVITY AND SPECIFICITY OF JOINT 18F-FDG UPTAKE ON WHOLE BODY PET/CT IN POLYMYALGIA RHEUMATICA.
Internal Medicine Journal.
24-24.
2017
-
Ayatti NLee SZakavi RPathmaraj KQatawneh LPoon AScott A. The effect of long acting somatostatin analogue administration on Ga-68-DOTATATE uptake in primary and metastatic NET lesions.
European Journal of Nuclear Medicine and Molecular Imaging.
S685-S686.
2017
Full text if available -
Pathmaraj KWelch JAckermann UScott A. [F-18]-DIHYDRO-TESTOSTERONE PET/CT IMAGING PROTOCOL FOR PATIENTS WITH ADVANCED PROSTATE CANCER.
Internal Medicine Journal.
21-21.
2017
-
Roach PFrancis REmmett LHsiao EKneebone AHruby GEade TNguyen QThompson BMcCarthy MTang CBrenner PStricker PScott A. Australian multicentre evaluation of clinical management intent utilising Ga68-PSMA PET scans in patients with prostate cancer.
European Journal of Nuclear Medicine and Molecular Imaging.
S165-S165.
2016
Full text if available -
Baker LPathmaraj KBerlangieri SStark CScott A. Botox therapy in simple partial seizures - evaluated with FDG PET and MRI.
Internal Medicine Journal.
11-11.
2016
-
van den Bent MGan HLassman AKumthekar PMerrell RButowski NLwin ZMikkelsen TNabors LPapadopoulos KPenas-Prado MSimes JWalbert TScott AGomez ELee H-JRoberts-Rapp LXiong HBain EHolen KMaag DReardon D. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM).
Neuro-Oncology.
vi2-vi2.
2016
Full text if available -
Sachinidis JPoniger STochon-Danguy HScott A. High yield radiolabeling of DOTA-TATE and PSMA with (68)Ga using the new MultiSyn radiosynthesizer.
Internal Medicine Journal.
42-43.
2016
Full text if available -
McDonald AAckermann UParslow AScott AWhite J. Investigation of novel Oncrasin-1 analogues for use in imaging kRAS mutant cancers.
Internal Medicine Journal.
41-42.
2016
Full text if available -
Chan JYoung KMulligan RScott ARowe C. METHOD DEVELOPMENT FOR QUALITY CONTROL AND VALIDATION OF SYNTHESIS OF 6-[18F]FLUORO-L-DOPA.
Internal Medicine Journal.
9-9.
2016
-
Owen CEPoon AMLee SYap L-PZwar RBMcMenamin CPathmaraj KKemp AScott ABuchanan RR. PET/MRI Fusion Demonstrates Hamstring Peri Tendonitis in Patients with Polymyalgia Rheumatica.
Annals of the Rheumatic Diseases.
567-568.
2016
Full text if available -
Atapattu LSaha NChheang CVail MEissman MErnst MScott ANikolov DJanes P. Selective inhibition of notch signalling and cancer stem cells by an antibody targeting active ADAM10.
European Journal of Cancer.
S194-S194.
2016
Full text if available -
Tochon-Danguy HAckermann UPoniger SChan GMorris MLewis JLyashchenko SScott A. Synthesis and in vivo imaging of 16 beta-[18f] fluoro-5 alpha-dihydrotestosterone in castration resistant prostate cancer.
Internal Medicine Journal.
42-42.
2016
Full text if available -
Chong LAckermann UGoh RKwan KRigopoulos AScott AO'Keefe GWhite J. Synthesis of fluorine-18 agents for pet imaging of hypoxic tissue in tumours.
Internal Medicine Journal.
36-37.
2016
Full text if available -
Chan JGYoung KMulligan RScott AMRowe CC. Validation of Quality Control Method for 6-[F-18]fluoro-L-DOPA.
European Journal of Nuclear Medicine and Molecular Imaging.
S471-S471.
2016
-
Mortensen ACSpiegelberg DScott AMLane DPNestor M. Enhancing the effect of radiotherapy in cultured tumour cells using p53 therapy.
European Journal of Nuclear Medicine and Molecular Imaging.
S429-S430.
2015
-
Spiegelberg DMortensen ACSelvaraju RKStenberg JScott ANestor M. Improving EGFR imaging by use of an anti-EGFRvIII monoclonal antibody: characterizations in an in vivo squamous cell carcinoma model.
European Journal of Nuclear Medicine and Molecular Imaging.
S467-S467.
2015
-
Spiegelberg DMortensen ACSelvaraju RKEriksson OStenerlow BScott ANestor M. Molecular imaging of EGFR and EGFRvIII for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.
European Journal of Nuclear Medicine and Molecular Imaging.
S263-S264.
2015
-
Scott AMAkhurst TLee FCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMurphy DHicks RLee SO'Keefe GGong SHudson P. Phase I Safety and Biodistribution Study of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer.
European Journal of Nuclear Medicine and Molecular Imaging.
S122-S122.
2015
-
Scott AMAkhurst TLee F-TCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMileshkin LWilliams SMurphy DHicks RPathmaraj KLee STO'Keefe GGong SOh MWheatcroft MHudson PJ. Abstract CT238: Phase I safety and biodistribution study of 124I-PEG-AVP0458 diabody in patients with TAG-72 positive ovarian and prostate cancer.
Cancer Research.
2015
Full text if available -
Burvenich ILee FTO'Keefe GJMakris DRamsland PALiu ZAllan LPerani ACao DRigopoulos AGong SGloria BScott AM. OPTIMIZING PHARMACOKINETICS AND TARGETING PROPERTIES OF RECOMBINANT ANTI-LEWIS Y ANTIBODY HU3S193 IN A431 TUMOR-BEARING MICE.
Internal Medicine Journal.
6-6.
2015
-
Scott AMAkhurst TLee F-TCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMileshkin LWilliams SMurphy DHicks RPathmaraj KLee STO'Keefe GJGong STochon-Danguy HPoniger SOh MWheatcroft MHudson PJ. PHASE I SAFETY AND BIODISTRIBUTION STUDY OF 124I-PEG-AVP0458 DIABODY IN PATIENTS WITH TAG-72 POSITIVE OVARIAN AND PROSTATE CANCER.
Internal Medicine Journal.
11-11.
2015
-
Smaletz ODiz MDPEDo Carmo CCSabbaga JCunha-Junior GFAzevedo SJMaluf FCBarrios CHCosta RLFontana AGMadrigal VWainstein AJYeda FPAlves VAMoro AMBlasbalg RScott AMHoffman EW. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
Gynecologic Oncology.
272-277.
2015
Full text if available -
Tang MPCMa RScott ALee SPathmaraj KBerlangieri SUCharles PGPatterson SJohnson DF. An earlier role for PET in the investigation of PUO? A 5-year retrospective cost benefit analysis.
Internal Medicine Journal.
19-19.
2015
Full text if available -
Tochon-Danguy HAckermann UPoniger SChan JGMorris MLewis JLyashchenko SScott A. Automated synthesis of 16 beta[F-18]fluoro-5 alpha-dihydrotestosterone using the FlexLab radiosynthesizer.
Journal of Nuclear Medicine.
2015
-
Ng WThomas DPathmaraj KLee SKao YGoodwin MScott A. BIODISTRIBUTION OF SIRSPHERES ON 90Y-PET/CT VS. BREMSSTRAHLUNG SPECT/CT IN PATIENTS WITH LIVER CARCINOMA.
Internal Medicine Journal.
40-40.
2015
-
Berlangieri SULee STSargeant JRoach PScott AM. COST EFFECTIVENESS ANALYSIS OF FDG PET/CT IN ADVANCED STAGE AND RECURRENT/METASTATIC BREAST CARCINOMA.
Internal Medicine Journal.
13-13.
2015
-
Ackermann UTochon-DAnguy HJSachinidis JScott AM. F-18 RADIOLABELLING OF DBCO AS A SYNTHON FOR COPPER FREE CLICK CHEMISTRY USING THE FLEXLAB MODULE.
Internal Medicine Journal.
32-32.
2015
-
Poniger SSTochon-Danguy HJPanopoulos HSachinidis JScott AM. FULLY AUTOMATED PRODUCTION OF ZR-89 USING IBA NIRTA AND PINCTADA SYSTEMS.
Internal Medicine Journal.
32-32.
2015
-
Roberts-Rapp LAnsell PKular RSong MSokolova IGan HPapadopoulos KPLassman ABMerrell RKumthekar PScott AGomez EFischer JBhathena AHolen KLai RReardon Dvan den Bent M. Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM).
Annals of Oncology.
ix8-ix9.
2015
Full text if available -
Van den Bent MJRoberts-Rapp LAnsell PKular RSong MSokolova IGan HPapadopoulos KPLassman ABMerrell RKumthekar PScott AGomez EFischer JBhathena AHolen KLai RReardon D. Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM).
European Journal of Cancer.
S585-S586.
2015
Full text if available -
Owen CPoon ALee SMcMenamin CPathmaraj KScott ABuchanan R. Incidence and Intensity of 18FDG Uptake on Whole Body PET/CT in Patients with Polymyalgia Rheumatica.
Arthritis and Rheumatology.
2015
Full text if available -
Lee FTBurvenich IJGGuo NKocovski PTochon-Danguy HAckermann UO'Keefe GJGong SRigopoulos ALiu ZGan HScott A. L‐tyrosine confers greater residualizing properties to a d‐amino acid rich residualizing peptide for radioiodination of internalizing antibodies.
Internal Medicine Journal.
5-6.
2015
Full text if available -
Di Biase MAZalesky ACropley VO'keefe GOlver JBaune BMcGorry PFornito AScott APhassouliotis CTahtalian SJones HShannon-Weickert CAllen LEverall IHickie IBanati RPantelis C. Microglial Activation: A PET Study in Schizophrenia.
Biological Psychiatry.
2015
-
Owen CPoon ALee STPathmaraj KBuchanan RScott AM. PROSPECTIVE STUDY OF WHOLE BODY FDG PET/CT IN PATIENTS WITH POLYMYALGIA RHEUMATICA.
Internal Medicine Journal.
21-21.
2015
-
Scott AAkhurst TLee F-TCiprotti MDavis IWeickhardt AHicks RLee STOh MHudson P. Phase I Safety and Biodistribution Study of I-124-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer.
Journal of Nuclear Medicine.
2015
-
Gan HKPapadopoulos KPFichtel LLassman ABMerrell RVan Den Bent MJKumthekar PScott AMPedersen MGomez EJFischer JSAmes WXiong HLee H-JMunasinghe WRoberts-Rapp LAnsell PHolen KDLai RReardon DA. Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
Journal of Clinical Oncology.
2015
Full text if available -
Chan JGYoung KAckerman UTochon-Danguy HScott A. Quality control validation of 16 beta-[18F]fluoro-5 alpha-dihydrotestosterone produced with the FlexLab radiosynthesiser.
European Journal of Nuclear Medicine and Molecular Imaging.
S488-S488.
2015
-
Alt KPaterson BArdipradja KPoniger SAckermann UPeter KTochon-Danguy HScott ADonnelly PHagemeyer C. Site-specific enzymatic and click chemistry bioconjugation of metal complexes to single-chain antibodies for PET/CT imaging of activated platelets.
Internal Medicine Journal.
5-5.
2015
Full text if available -
Chappell BToohey JPoon ALee STScott A. USE OF DIRECT INTRANODAL INJECTION OF (TC)-T-99M-RHENIUM COLLOID FOR LYMPH NODE LOCALISATION: A CASE STUDY.
Internal Medicine Journal.
26-26.
2015
-
Gan HKFichtel LLassman ABMerrell RVan Den Bent MJKumthekar PScott AMPedersen MGomez EFischer JAmes WXiang HDudley MWMunasinghe WRoberls-Rapp LAnsell PHolen KDReardon DA. A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
Journal of Clinical Oncology.
2014
Full text if available -
Chionh FJMGebski VChueh ACAl-Obaidi SJWelckhardt AJLee CWilliams DSMurone CWilson KScott AMSimes JPrice TJMariadason JMTebbutt NC. Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX Inter study..
Journal of Clinical Oncology.
2014
Full text if available -
Chang JLim-Joon DDavis ILee SHiew CEsler SWada MBolton DScott AKhoo V. A comparison of 11C-choline PET with T2-weighted MRI for localizing malignant intraprostatic lesions for guiding prostate cancer focal therapies.
BJU International.
33-33.
2014
-
Wichmann CWhite JTochon-Danguy HJScott AMRigopoulos AO'Keefe GAckermann U. A NOVEL F-18 LABELLED ANILINO SULPHOXIDE FOR PET IMAGING OF TUMOUR HYPOXIA.
Internal Medicine Journal.
36-36.
2014
-
Gan HKFichtel LLassman ABMerrell Rvan den Bent MKumthekar PScott AMPedersen MGomez EFischer JAmes WXiong HDudley MMunasinghe WRoberts-Rapp LAnsell PHolen KReardon DA. A PHASE 1 STUDY EVALUATING ABT-414 WITH TEMOZOLOMIDE (TMZ) OR CONCURRENT RADIOTHERAPY (RT) AND TMZ IN GLIOBLASTOMA (GBM).
Neuro-Oncology.
2014
Full text if available -
Gan HFichtel LLassman AMerrell Rvan den Bent MJKumthekar PScott APedersen MGomez EFischer JAmes WXiong HDudley MRoberts-Rapp LAnsell PJHolen KReardon DA. A phase 1 study evaluating ABT-414 with concurrent radiotherapy (RT) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).
Annals of Oncology.
2014
Full text if available -
Lee STGong SJHickson KRigopoulos AAckermann UO'Keefe GJScott AM. ASSESSING METABOLIC AND HYPOXIC CHANGES TO TREATMENT IN COLORECTAL XENOGRAFTS WITH NANOPET/MRI.
Internal Medicine Journal.
30-31.
2014
-
Chang JHJoon DLDavis IDLee STHiew CYEsler SGong SJWada MClouston DO'Sullivan RGoh YPBolton DKhoo VScott AM. C-11-CHOLINE PET IS SUPERIOR TO T2-WEIGHTED MRI FOR LOCALISING MALIGNANT INTRAPROSTATIC LESIONS FOR GUIDING PROSTATE CANCER FOCAL THERAPIES.
Internal Medicine Journal.
13-14.
2014
-
Chappell BToohey JLee STScott A. FACTORS AFFECTING DOSE OPTIMISATION IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA.
Internal Medicine Journal.
37-37.
2014
-
Woo JLee STBerlangieri SPoon AMTPathmaraj KSachinidis JChan GJScott AM. FUNCTIONAL IMAGING WITH (68)GA-DOTATATE PET/CT SCAN IN PATIENTS WITH NEUROENDOCRINE TUMOURS.
Internal Medicine Journal.
8-8.
2014
-
Charmsaz SMiller KJDay BWEl-Ajeh FPalath VYarranton GTBebbington CRScott AMLackmann MBoyd AW. Immunotherapeutic Targeting of EphA3.
Blood.
2014
Full text if available -
Orcutt KAdams GWu ASilva MHoppin JMatsumura MKotsuma MGreenberg JScott ABeckman R. Molecular simulation of receptor occupancy and tumor penetration of an antibody and smaller scaffolds: Application to molecular imaging.
Journal of Nuclear Medicine.
2014
-
Scott A. Novel antibody scaffolds for therapy of solid tumours.
Asia Pacific Journal of Clinical Oncology.
23-23.
2014
Full text if available -
Lau LLee STWilliams DChristophi CMuralidharan VScott AM. PROGNOSTICATOR SHOWDOWN: METABOLIC VS PATHOLOGICAL RESPONSE TO PREOPERATIVE CHEMOTHERAPY FOR COLORECTAL LIVER METASTASES.
Internal Medicine Journal.
16-16.
2014
-
Yeung YChionh FPrice TJScott ATran HFang GSkrinos EMurone CMariadason JTebbutt N. Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol..
Journal of Clinical Oncology.
4101-4101.
2014
Full text if available -
Lau LWilliams DScott AChristophi CMuralidharan VLee ST. Prognostication with metabolic and pathological response to preoperative chemotherapy in colorectal liver metastases.
Journal of Nuclear Medicine.
2014
-
Orcutt KDAdams GPWu AMSilva MHoppin JHarwell CMatsumura MKotsuma MFreeman DTse AGreenberg JScott ABeckman RA. Receptor occupancy and tumor penetration by antibodies, peptides, and antibody fragments: Molecular simulation of imaging assessment.
Cancer Research.
2014
Full text if available -
Kao YHLee STSchelleman AGoodwin MScott AM. SURVIVAL OUTCOMES FOR RADIOEMBOLISATION OF INOPERABLE LIVER MALIGNANCIES USING YTTRIUM-90 RESIN MICROSPHERES: AUSTIN HOSPITAL EXPERIENCE.
Internal Medicine Journal.
37-37.
2014
-
Ackermann UTochon-Danguy HJPoniger SSDavis IScott AM. SYNTHESIS OF F-18 FLUOROESTRADIOL USING THE FLEXLAB SYSTEM.
Internal Medicine Journal.
35-35.
2014
-
Chan JGYoung KIftikhar FSachinidis JIAckermann UScott AM. Validation of Quality Control of 68Ga-DOTA-TATE.
European Journal of Nuclear Medicine and Molecular Imaging.
S438-S438.
2014
-
Welch JBerlangieri SLee STPathmaraj KScott A. WHOLE BODY FDG-PET/CT IMAGING IN A PREGNANT WOMAN - IS IT SAFE?.
Internal Medicine Journal.
34-34.
2014
-
Charmsaz SDay BEl-Ajeh FPalath VYarranton GBebbington CScott ALackmann MBoyd A. EPHA3 IS A THERAPY TARGET FOR LEUKAEMIA AND OTHER CANCERS.
Experimental Hematology.
S52-S52.
2013
Full text if available -
Neeson PRitchie DKhot APeinert STai THonemann DGambell PWesterman DWestwood JScott AKravets LDickinson MTrapani JSmyth MDarcy PKershaw MPrince H. In vivo trafficking, persistence and efficacy of Lewis-Y chimeric antigen receptor T cells in patients with Lewis-Y positive acute myeloid leukaemia.
Journal of Immunology.
2013
-
Ciprotti MTebbutt NLee FTLee STMcKee DO'Keefe GGong SChappell BBeckmann RScott A. A PHASE I IMAGING AND PHARMACODYNAMIC TRIAL OF CS-1008 IN PATIENTS WITH METASTATIC COLORECTAL CANCER.
Internal Medicine Journal.
9-9.
2013
-
Chan GYoung KGong SHickson KScott A. A PRELIMINARY REVIEW OF PET DOSE DISPENSING PRACTICES WITH EXTREMITY MEASUREMENTS.
Internal Medicine Journal.
32-32.
2013
-
Gan HBurge MESolomon BJHolen KDZhang YCiprotti MMerdan TMunasinghe WPedersen MHintzman PFFox GBHumerickhouse RAScott A. A phase I and biodistribution study of ABT-806i, an (111)indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806..
Journal of Clinical Oncology.
2013
Full text if available -
Ciprotti MTebbutt NCLee FTLee STMcKee DCO'Keefe GJGong SJChong GGan HKHopkins WChappell BScott FEBrechbiel MWTse ANJansen MMatsumura MWatanabe RBeckman RAGreenberg JScott AM. A phase I imaging and pharmacodynamic trial of CS-1008 in patients (pts) with metastatic colorectal cancer (mCRC)..
Journal of Clinical Oncology.
2013
-
Chan JGYoung KHickson KGong SO'Keefe GJScott AM. A practical evaluation of effectiveness of commonly used syringe shields for PET dose dispensing.
European Journal of Nuclear Medicine and Molecular Imaging.
S321-S321.
2013
-
Khot ARitchie DNeeson PPeinert STai TKravets LChen KHoenemann DShin MTainton KWestwood JKershaw MHaurat JTrapani JSmyth MDarcy PScott AWall DGambell PDickinson MWesterman DHicks RPrince M. AUTOLOGOUS PERIPHERAL BLOOD T LYMPHOCYTES TRANSDUCED WITH AN ANTI LEWISY CHIMERIC RECEPTOR GENE CAN BE INFUSED SAFELY AND PERSIST IN PATIENTS WITH LEWISY POSITIVE ACUTE MYELOID LEUKAEMIA.
Cytotherapy.
S14-S14.
2013
Full text if available -
Tochon-Danguy HPoniger SPanopoulos HO'Keefe GSachinidis JScott A. AUTOMATED PRODUCTION OF 124I AND 64CU USING IBA TERIMO AND PINCTADA METAL ELECTROPLATING AND PROCESSING MODULES.
Internal Medicine Journal.
37-37.
2013
-
Scott A. Advances in imaging for GU Oncology.
Asia Pacific Journal of Clinical Oncology.
26-26.
2013
-
Ng WLee STWelch JDesmond SSaleem SPathmaraj KWright SScott AMBerlangieri SRowe C. CORONARY ARTERY CALCIUM SCORING ON ROUTINE PET/CT.
Internal Medicine Journal.
1-1.
2013
-
Tochon-Danguy HGoh YWYeoh SDPlougastel LSachinidis JIPoniger SScott AMAckermann U. FULLY AUTOMATED CLICK RADIOLABELLING AND THE SYNTHESIS AND COUPLING OF [18F]FBEM TO GLUTATHIONE USING THE IPHASE FLEXLAB MODULE.
Internal Medicine Journal.
14-14.
2013
-
Goh YWPlougastel LYeoh SDSachinidis JTochon-Danguy HPoniger SScott AMAckermann U. Fully automated Click radiolabeling and the synthesis and coupling of [F-18]FBEM to glutathione using the iPhase Flexlab module.
Journal of Labelled Compounds and Radiopharmaceuticals.
S451-S451.
2013
-
Lau LMuralidharan VLee STO'Keefe GChristophi CScott A. Metabolic Response to Preoperative Chemotherapy Predicts Prognosis in Colorectal Liver Metastases.
Internal Medicine Journal.
6-7.
2013
-
Hickson KO'Keefe GGong SScott A. NEMA NU2 2007 PERFORMANCE MEASUREMENTS AND COMPARISONS OF 2ND AND 3RD GENERATION GEMINI TIME-OF-FLIGHT PET/CT SCANNERS.
Internal Medicine Journal.
32-32.
2013
-
Feigen MKupfer THamilton CLee SScott AMcDonald CFLawlor MChurcher K. Outcomes From Radiation Pneumonectomy for Locally-Advanced Malignant Pleural Mesothelioma: High Locoregional Control Rate With Acceptable Toxicity.
International Journal of Radiation: Oncology - Biology - Physics.
S114-S114.
2013
Full text if available -
Mertens LSMir CScott AMLee S-TBruining AVegt EVogel WVManecksha RBolton DHorenblas SDavis IDVan Rhijn BWGLawrentschuk N. PET/CT predicts mortality in muscle invasive bladder cancer.
BJU International.
71-71.
2013
Full text if available -
O'Keefe GGong SHickson KRigopoulos ACao DFrewin MScott A. PRE-CLINICAL IMAGING DEVELOPMENTS AT THE ACRF CENTRE FOR TRANSLATIONAL CANCER RESEARCH AND IMAGING.
Internal Medicine Journal.
24-24.
2013
-
Jackson JEWada MLee STGan HPoon AGong SGunawardana DJoon DLHamilton CScott A. Pre‐Radiotherapy [18F]‐Fluoromisonidazole PET Is Predictive of Long Term Local Control and Survival in Head and Neck Cancer.
Internal Medicine Journal.
7-7.
2013
Full text if available -
Pathmaraj KScott A. QUALITY ASSURANCE IN NUCLEAR MEDICINE AND PET.
Internal Medicine Journal.
40-40.
2013
-
Ackermann USong DYeoh SDGoh YWTochon-Danguy HScott AWhite J. SYNTHESIS AND EVALUATION OF A PEGYLATED F-18 LABELLED NITROPHENYL SULFOXIDE FOR PET IMAGING OF TUMOUR HYPOXIA.
Internal Medicine Journal.
11-12.
2013
-
Ackermann USong DYeoh SDGoh YWTochon-Danguy HScott AWhite J. Synthesis and evaluation of a pegylated F-18 labelled nitrophenyl sulfoxide for PET imaging of tumor hypoxia.
Journal of Labelled Compounds and Radiopharmaceuticals.
S355-S355.
2013
-
Poniger SSTochon-Danguy HJPanopoulos HPO'Keefe GJPeake DRasool RScott AM. Automated production of 124I and 64Cu using IBA Terimo and Pinctada metal electroplating and processing modules.
AIP Conference Proceedings.
114-119.
2012
Full text if available -
Tochon-Danguy HJPoniger SSSachinidis JIPanopoulos HPScott AM. Implementation of a solid target production facility.
AIP Conference Proceedings.
176-180.
2012
Full text if available -
Solomon BDesai JScott ARosenthal MMcArthur GRischin DSegelov EMacDiarmid JBrambhatt H. 585 First-in-man, Multicenter, Phase I Trial Evaluating the Safety of First-in-class Therapeutic, EGFR-targeted, Paclitaxel-Packaged Minicells.
European Journal of Cancer.
179-179.
2012
Full text if available -
Gong SJAckermann UO'Keefe GJCartwright GRigopoulos ACao DArdipradja KLee FTTochon-Danguy HScott AM. PET Image-derived Biodistribution and Dose Assessment of C-11-AG1478 in BALB/c Mice with A431 EGFR-positive Xenografts.
European Journal of Nuclear Medicine and Molecular Imaging.
S324-S324.
2012
-
Gong SJMong LHickson KYoung KWelch JDesmond SPathmaraj KSachinidis JChan GTochon-Danguy HPaul UO'Keefe GScott AM. A FEASIBILITY STUDY OF USING INSTADOSE PERSONAL DOSIMETERS IN A PET FACILITY.
Internal Medicine Journal.
44-44.
2012
-
Hickson KO'Keefe GBradley JRamdave SMcKay WJScott AM. A GIBBS ARTIFACT IN PET IMAGES RECONSTRUCTED WITH THE TRUEX ALGORITHM.
Internal Medicine Journal.
42-42.
2012
-
Ackermann UChong LWYeoh SDRigopoulos ATochon-Danguy HWhite JO'Keefe GScott AM. A NOVEL NITROFURAN FOR THE IMAGING OF TUMOUR HYPOXIA.
Internal Medicine Journal.
9-9.
2012
-
Lee STDavis IDGong SJShanker LClouston DBolton DMAngus DWebb DLawrentschuk NWoon TSJoon DLChang JHEsler SO'Sullivan RPathmaraj KTochon-Danguy HO'Keefe GScott AM. C-11-CHOLINE PET SCANNING IS MORE ACCURATE THAN BIOPSY IN ASSESSMENT OF LOCALIZED PROSTATE CANCER PLANNED FOR RADICAL PROSTATECTOMY.
Internal Medicine Journal.
26-26.
2012
-
Liew MSMurone CWalkiewicz MMitchell PGan HBarnett SRussell PWright GScott AJohn T. CORRELATION OF WTEGFR ACTIVATION ASSESSED BY MAB806 BINDING AND EGFR KINASE MUTATIONS IN STAGE IIIA N2 NSCLC.
Annals of Oncology.
542-542.
2012
-
Feigen MLee SScott AMHamilton C. Clinical Outcomes Of High-dose Hemithoracic Radiotherapy In Patients With Unresected Pleural Mesothelioma - Impressive Locoregional Control Confirmed By Pet/ct Scan Assessments.
Journal of Thoracic Oncology.
S305-S305.
2012
-
Hickson KO'Keefe GScott AM. EFFECT OF VOXEL SIZE WHEN CALCULATING PATIENT SPECIFIC RADIONUCLIDE DOSIMETRY ESTIMATES USING DIRECT MONTE CARLO SIMULATION.
Internal Medicine Journal.
42-42.
2012
-
Saleem SPathmaraj KLee STBerlangieri SUScott AM. F-18-FDG PET IN THE MANAGEMENT OF LYMPHOMATOID GRANULOMATOSIS.
Internal Medicine Journal.
29-29.
2012
-
Ng WLee STBerlangieri SUWelch JDesmond SSaleem SPathmaraj KScott AM. F-18-FDG UPTAKE IN BOWEL IN DIABETIC PATIENTS TREATED WITH METFORMIN.
Internal Medicine Journal.
28-28.
2012
-
Tan GLee STBerlangieri SUScott AM. FDG-PET/CT FINDINGS IN TOPHACEOUS GOUT.
Internal Medicine Journal.
38-38.
2012
-
Chang JHWada MAnderson NJJoon DLLee STGong SJGunawardana DO'Keefe GKhoo VScott AM. HYPOXIA-TARGETED RADIOTHERAPY USING FMISO PET IMPROVES TUMOUR CONTROL IN HEAD AND NECK CANCER.
Internal Medicine Journal.
23-23.
2012
-
Tochon-Danguy HPoniger SSachinidis JPanopoulos HO'Keefe GRassool RScott AM. IMPLEMENTATION OF A SOLID TARGET FACILITY AT AUSTIN HEALTH FOR THE PRODUCTION OF CU-64 AND I-124.
Internal Medicine Journal.
7-8.
2012
-
Boktor RLee STBerlangieri SUScott AM. MANAGEMENT IMPACT OF FDG PET/CT IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA: A COMPARATIVE STUDY WITH I-131 WHOLE BODY SCAN AND SERUM THYROGLOBULIN.
Internal Medicine Journal.
23-23.
2012
-
Pathmaraj KWelch JGong SJHickson KO'Keefe GChan GScott AM. ONGOING STRATEGIES TO MANAGE RADIATION EXPOSURE TO PET STAFF DURING DOSE DISPENSING, DOSE ADMINISTRATION AND PATIENT POSITIONING.
Internal Medicine Journal.
15-15.
2012
-
Feigen MLee SLawlor MScott AMHamilton C. RADIATION "PNEUMONECTOMY" FOR LOCALLY ADVANCED MALIGNANT PLEURAL MESOTHELIOMA: ACCEPTABLE LOCOREGIONAL CONTROL AND TOXICITY OUTCOMES.
Journal of Thoracic Oncology.
S166-S166.
2012
-
Hickson KO'Keefe GYoung KChan GIftikhar FScott AM. THE RADIATION FINGER DOSE OF SENIOR AND JUNIOR STAFF USING AUTOMATED RADIOPHARMACEUTICAL DISPENSING.
Internal Medicine Journal.
15-15.
2012
-
Chang JHJoon DLLee STGong SJClouston DDavis IDHamilton CSKhoo VScott AM. TUMOUR DELINEATION FOR PROSTATE CANCER RADIOTHERAPY USING C-11-CHOLINE PET SCANS: AN IMAGING-PATHOLOGY CORRELATION STUDY.
Internal Medicine Journal.
16-16.
2012
-
Welch JDesmond SPathmaraj KLee STBerlangieri SUScott AMRowe CC. WHEN IS A HIGH BLOOD GLUCOSE LEVEL TOO HIGH FOR FDG-PET BRAIN IMAGING FOR DEMENTIA?.
Internal Medicine Journal.
6-6.
2012
-
Davis ILee STClouston DShanker LBolton DEsler STochon-Danguy HO'Keefe GGong SScott A. 11C-Choline PET scanning is more accurate than biopsy in assessment of localized prostate cancer planned for radical prostatectomy.
Journal of Nuclear Medicine.
2012
-
Boktor RLee STBeriangieri SScott A. Management impact of FDG PET/CT in patients with differentiated thyroid carcinoma: A comparative study with I-131 whole body scan and serum thyroglobulin.
Journal of Nuclear Medicine.
2012
-
Mir MCPapa NManecksha RBolton DDavis IScott ALawrentschuk N. Positron emission tomography-computed tomography (PET-CT) role in predicting mortality in patients with metastatic bladder cancer.
BJU International.
40-40.
2012
-
Neeson PKhot ASPeinert STai TYChen KTainton KWall DHoenemann DKershaw MHWestwood JTrapani JSmyth MJDarcy PScott AKravets LDavison JDickinson MJRitchie DPrince M. Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewis(y) Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer.
Blood.
1788-1789.
2011
-
Chan JGYoung KScott AM. Observed interference effects of reagent water in critical HPLC analysis.
European Journal of Nuclear Medicine and Molecular Imaging.
S298-S298.
2011
-
Davis ICiprotti MLee FPook DCavicchiolo TLee SChappell BO'Keefe GTochon-Danguy HHopkins WScott A. A PILOT STUDY OF THE SAFETY, EFFICACY, AND EFFECTS ON FUNCTIONAL IMAGING OF THE COMBINATION OF cG250 AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC).
Internal Medicine Journal.
11-11.
2011
-
Ackermann UTochon-Danguy HYeoh SSachinidis JScott A. IMPLEMENTATION OF AN IN VITRO ASSAY FOR PHASE 1 METABOLISM OF PET RADIOTRACERS.
Internal Medicine Journal.
30-30.
2011
-
Lee SChang JJoon DLGong SAnderson NDavis IClousten DBolton DHamilton CKhoo VScott A. IMRT DOSE PAINTING FOR LOCALISED PROSTATE CARCINOMA USING C-11-CHOLINE PET SCAN.
Internal Medicine Journal.
12-12.
2011
-
Scott ALee FCartwright GO'Keefe GBeckman RFujiwara Kvon Romeling R. MOLECULAR IMAGING OF DEATH RECEPTOR 5 (DR5) OCCUPANCY IN-VIVO BY HUMANIZED MONOCLONAL ANTIBODY CS-1008.
Internal Medicine Journal.
18-18.
2011
-
Lee SLau LMuralidharan VKwok MO'Keefe GChristophi CScott A. TOTAL GLYCOLYTIC VOLUME (TGV) IS A PROGNOSTIC INDICATOR IN COLORECTAL LIVER METASTASES.
Internal Medicine Journal.
17-18.
2011
-
Smaletz ODiz MDPCarmo CCSabbaga JCunha GFAzevedo SJMaluf FCBarrios CHCosta RLFontana AGAlves VAMoro AMScott AMHoffman EWOld LJ. Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC)..
Journal of Clinical Oncology.
5078-5078.
2011
Full text if available -
Burvenich IJLee FTO'Keefe GMakris DRamsland PALiu ZAllan LPerani ACartwright GCao DRigopoulos AGong SGloria BMurphy RScott AM. Abstract 5318: Optimizing pharmacokinetics and targeting properties of recombinant anti-Lewis Y antibody hu3S193 in A431 tumor-bearing mice.
Cancer Research.
2011
Full text if available -
Greenall SGherardi EScott AJohns TG. Abstract 636: C-Met antibodies with distinctive characteristics including induction of receptor degradation without activation and tumor specificity.
Cancer Research.
2011
Full text if available -
Yeoh SDSachinidis JTochon-Danguy HScott AMAckermann U. Automated production of [F-18] 2-fluoroethyl azide and a thymidine analogue using the Synthera module.
Journal of Labelled Compounds and Radiopharmaceuticals.
S416-S416.
2011
-
Goh YWYeoh SDTochon-Danguy HScott AMAckermann U. Implementation of an in vitro assay for phase 1 metabolism of PET radiotracers.
Journal of Labelled Compounds and Radiopharmaceuticals.
S67-S67.
2011
-
Laurens EAckermann UWhite JMTochon-Danguy HYeoh SDRigopoulos AScott A. Synthesis and biological evaluation of novel fluoro-18 labeled positron emission tomography (pet) imaging agents for hypoxic tissues in tumours.
Journal of Labelled Compounds and Radiopharmaceuticals.
S187-S187.
2011
-
Palath VVekhande RBaer MChing WTomasevic NMartinez DYi CBhaskar SLuehrsen KWilliams JLeung JList AFZhang LLackmann MBoyd AScott ACilloni DYarranton GBebbington C. A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples.
Blood.
2897-2897.
2010
Full text if available -
Scott AMLee FTCartwright GCO'Keefe GJBeckman RAFujiwara Kvon Roemeling R. 240 Molecular imaging of Death Receptor 5 (DR5) occupancy in-vivo by humanized monoclonal antibody CS-1008.
European Journal of Cancer, Supplement.
78-78.
2010
Full text if available -
Chang JHLim Joon DDavis IDScott AMLee STClouston DKhoo VHamilton CS. Validation of 11C-choline and 18F-FDG PET Scans with Pathology for Radiotherapy Target Definition in Prostate Cancer.
International Journal of Radiation: Oncology - Biology - Physics.
S379-S380.
2010
Full text if available -
Bauer SFischer EWueest TScott AMSchibli RRitter GOld LJRenner C. Antibody targeting of epithelial carcinoma associated fibroblast activation protein blocks cellular proliferation, migration and invasion.
Onkologie: international journal for cancer research and treatment.
286-286.
2010
-
Lee FTGong SRamachandran MWalkiewicz MRigopoulos ACao DCartwright GBurvenich IO'Keefe GScott A. IMMUNO-POSITRON EMISSION TOMOGRAPHY (PET) OF LEWIS Y (LEY) EXPRESSING XENOGRAFTS USING 89ZR-LABELLED HUMANISED ANTIBODY HU3S193.
Annals of Oncology.
58-58.
2010
-
Gong SJLee STO'Keefe GBerlangieri SPathmaraj KTochon-Danguy HDavis IDScott AM. Investigating the Optimum Imaging Time Window for Assessing Prostate Cancer with Positron Emission Tomography Using C-11-Choline.
European Journal of Nuclear Medicine and Molecular Imaging.
S325-S326.
2010
-
Chan JGHickson KJO'Keefe GJYoung KTochon-Danguy HJPoniger SSScott AM. Minimising radiation exposure of PET radiopharmacists following implementation of Tema uDDS-A automatic dose dispensing system and optimising work practices.
European Journal of Nuclear Medicine and Molecular Imaging.
S364-S364.
2010
-
Chang JJoon DLLee STGong SClouston DShankar LKhoo VDavis IScott AHamilton C. TUMOUR DELINEATION FOR PROSTATE CANCER RADIOTHERAPY USING 18F-FDG AND 11C-CHOLINE PET SCANS: A PATHOLOGY-IMAGING CORRELATION STUDY.
Radiotherapy and Oncology.
S89-S89.
2010
-
Bauer SFischer EWuest TScott AMSchibli RRitter GOld LJRenner C. Antibody targeting of epithelial carcinoma-associated fibroblast activation protein blocks cellular proliferation, migration, and invasion..
Journal of Clinical Oncology.
e13062-e13062.
2010
Full text if available -
Weickhardt AJPrice TJPavlakis NSkrinos EDobrovic ASalemi RScott AMMariadason JChong GTebbutt NC. DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer..
Journal of Clinical Oncology.
3533-3533.
2010
Full text if available -
Desai JSolomon BJDavis IDLipton LRHicks RScott AMPark JClemens PLGestone TAFinckenstein FG. Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.
Journal of Clinical Oncology.
2010
-
Lawrentschuk NMurone CPoon AMTJohns-Putra LDavis IDBolton DMScott AM. 575 AN ASSESSMENT OF TISSUE HYPOXIA IN HUMAN RENAL TUMOURS IN PATIENTS UNDERGOING NEPHRECTOMY USING “GOLD-STANDARD” DIRECT OXYGEN PROBE MEASUREMENTS AND IMMUNOHISTOCHEMISTRY.
European Urology, Supplements.
195-195.
2010
Full text if available -
Wong PLee STMurone CLawrentschuk NDavis IDBolton DMScott AM. In-vivo imaging of cellular proliferation in renal cell carcinoma using [18]F fluorothymidine PET.
BJU International.
22-22.
2010
-
Palath VVekhande RLee AWilliams JZhang LList AFBoyd ALackmann MScott AMCilloni DYarranton GTBebbington C. A Recombinant Human Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Shows Selective Cytotoxicity against Myeloid Leukemia Cells and CD123-Positive Leukemic Stem Cells..
Blood.
1728-1728.
2009
Full text if available -
Chang JHLim Joon DAnderson NJDavis ILee STGong SShanker LScott AHamilton CS. The Feasibility of Delivering an IMRT Boost to the 11C-Choline-PET-defined Dominant Intraprostatic Lesion.
International Journal of Radiation: Oncology - Biology - Physics.
S323-S323.
2009
Full text if available -
Davis IDLee SBolton DMClouston DDamianovich DPezaro CAngus DJenkins TFong CScott AM. A pilot study to determine correlation of positron emission tomography (PET), histopathology and PSA levels in prostate cancer (PC) patients (pts) undergoing neoadjuvant docetaxel chemotherapy.
European Journal of Nuclear Medicine and Molecular Imaging.
S172-S172.
2009
-
Feigen MLee STWada MO'Keefe GLawford CLawlor MScott AM. Assessing the efficacy of radiotherapy for local control of malignant pleural mesothelioma using total glycolytic voluming of serial 18F-FDG PET scans.
Journal of Thoracic Oncology.
S756-S756.
2009
-
Azad AChionh FScott AMLee S-TBerlangieri SUWhite SMitchell PL. High impact of staging 18F-FDG-PET on prognostic stratification of newly diagnosed small cell lung cancer (SCLC).
Journal of Thoracic Oncology.
S461-S462.
2009
-
Wada MAnderson NScott ALawford C. DOSE PAINTING UTILISING FMISO HYPOXIC SUB-VOLUMES AND BENEFITS OF BIOLOGICAL OPTIMISATION IN THE MANAGEMENT OF ADVANCED HEAD AND NECK CANCERS.
Radiotherapy and Oncology.
S201-S201.
2009
Full text if available -
Chang JJoon DLAnderson NLee STGong SKhoo VDavis IScott AHamilton C. SIMULTANEOUS INTEGRATED BOOST TO THE 11 C-CHOLINE-PET-DEFINED DOMINANT INTRAPROSTATIC LESION: A TECHNICAL FEASIBiLITY STUDY.
Radiotherapy and Oncology.
S78-S78.
2009
Full text if available -
Peinert SHoenemann DRitchie DGuru PHarrison SWesterman DKershaw MSmyth MTrapani JDarcy PShin AGambell PScott ANeeson PPrince HM. TARGETING LEWIS Y-EXPRESSING MULTIPLE MYELOMA AND ACUTE MYELOID LEUKEMIA WITH GENE-MODIFIED T CELLS DEMONSTRATING MEMORY PHENOTYPE.
Haematologica: the hematology journal.
26-26.
2009
-
Azad AChionh FScott AWhite SMitchell PL. Staging (18)FDG-PET in newly diagnosed small cell lung cancer (SCLC): 15-year institutional experience.
Journal of Clinical Oncology.
2009
-
Burvenich IAllan LRamsland PLiu ZPerani ACartwright GLee FCao DRigopoulos AGloria BScott A. Homology modeling based site-directed mutagenesis of anti-Le(y) antibody hu3S193 Fc:FcRn interactions.
Cancer Research.
2009
-
Wong PLee SDavis IScott ABolton D. In vivo measurement of hypoxia in a renal cell carcinoma xenograft model.
BJU International.
40-40.
2009
-
Ackermann UO'Keefe GRigopoulos ACao DGong STochon-Danguy HScott A. IMAGING OF THE EGF RECEPTOR IN A431 TUMOR BEARING MICE USING C-11 AG1478.
Journal of Labelled Compounds and Radiopharmaceuticals.
S382-S382.
2009
-
Laurens EAckermann UWhite JTochon-Danguy HYeoh SScott A. SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL FLUORO-18 LABELED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS FOR HYPOXIC TISSUES.
Journal of Labelled Compounds and Radiopharmaceuticals.
S197-S197.
2009
-
Ackermann UTochon-Danguy HJSachinidis JIPoniger SSScott AM. Click chemistry with [F-19/F-18] 2-fluoroethylazide -radiolabelling and reaction kinetics of an FLT analogue.
European Journal of Nuclear Medicine and Molecular Imaging.
S153-S153.
2008
-
O'Keefe GJZavala JSaunder TTochon-Danguy HChan GMa HPerera NScott ARowe CDonnan G. Inflammation Imaging in Ischaemic Stroke using [11C]PK11195.
European Journal of Nuclear Medicine and Molecular Imaging.
S309-S310.
2008
-
Garrett TPJLuo CXu YHuyton TAdams TGWalker FNice ECBurgess AWScott AMJohns TG. Therepeutic antibodies target a locally misfolded region of tumour-specific EGFR.
Acta Crystallographica Section A: Foundations and Advances.
C347-C347.
2008
Full text if available -
Renner COosterwijk EAdrian NOosterwijk-Wakka JCohen LRitter GKnuth ADivgi CRScott AMOld LBauer S. Synergistic therapeutic activity of chimeric G250-TNF and IFNγ for the treatment of renal cell cancer.
Journal of Clinical Oncology.
16009-16009.
2008
Full text if available -
He JO'Keefe GJJones GSaunder TGong SJGeso MScott AM. Evaluation of geometrical sensitivity for respiratory motion gating by GATE and NCAT simulation.
Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings.
4165-4168.
2007
Full text if available -
Oriuchi NHiguchi TIshikita THanaoka HIida YYoshioka HScott AMSakamoto JHoffman EEndo K. Biodistribution, safety, and pharmacokinetics of humanized monoclonal antibody huA33 in patients with gastric carcinoma determined by I-131-labeled huA33.
European Journal of Nuclear Medicine and Molecular Imaging.
S360-S360.
2007
-
Falzon CLAckermann UTochon-Danguy HScott ASpratt NHowells DFernandez JRewell S. Evaluation of novel PET imaging agents for the identification of the ischemic penumbra in stroke.
European Journal of Nuclear Medicine and Molecular Imaging.
S332-S332.
2007
-
Fulham MJKelley BRamshaw JEScott AM. Impact of FDG PET on the management of patients with suspected or proven metastatic melanoma prior to surgery: A prospective, multi-centre study as part of the Australian PET Data Collection Project.
European Journal of Nuclear Medicine and Molecular Imaging.
S153-S153.
2007
-
Kelly MPLee FTTahtis KSmyth FEBrechbiel MWScott AM. Radioimmunotherapy with -Particle-Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy.
Clinical Cancer Research.
5604s-5612s.
2007
Full text if available -
Scott AMGunawardana DKelly BStuckey JByrne ARanshaw JFulham M. F-18-FDG PET changes management and improves prognostic stratification in patients with colorectal cancer: results of a prospective, multi-centre study.
Journal of Clinical Oncology.
2007
-
Chatterton BEHo-Shon ILenzo NPatrikeos AKelley BBaldey ARamshaw JScott A. Multi-centre prospective assessment of accuracy and impact on management of positron emission tomography (PET) in esophageal and gastroesophageal junction cancers (EC). Australian PET Data Collection Project.
Journal of Clinical Oncology.
2007
-
Herbertson RATebbutt NGill SLee FTChappell BCavicchiolo TSkrinos EPoon ASaunder TScott AM. Targeted chemoradiation for metastatic colorectal cancer: A phase I trial of oral capecitabine combined with I-131-huA33.
Journal of Clinical Oncology.
2007
-
Wong PLee STMurone CLawrentschuk NBerlangieri SPathmaraj KO'Keefe GSachinidis JByrne ADavis IBolton DScott A. In vivo molecular imaging of proliferation in renal cell carcinoma using F-18-fluorodeoxythymidine (FLT) positron emission tomography.
BJU International.
18-19.
2007
-
Jianfeng HeO'Keefe GJGong SJSaunder TJones GScott AMMoshi Geso. Investigation of respiratory motion gating with geometric sensitivity in Allegro PET.
IEEE Nuclear Science Symposium Conference Record.
4336-4344.
2007
Full text if available -
Johns TGPerera RMLuwor RBCavenee WKScott AMFurnari FB. EGFR levels, activation status and heterodimerization all influence the in vivo antitumor activity of EGFR-specific antibodies in glioma.
Neuro-Oncology.
428-428.
2006
-
He JO'Keefe GJJones GSaunder TGong SJGeso MScott AM. The Application of GATE and NCAT to Respiratory Motion Simulation in Allegro PET.
IEEE Nuclear Science Symposium Conference Record.
2589-2593.
2006
Full text if available -
Kitano SHirayama MKageyama SNagata YNishikawa MScott AMMurphy RHoffman EWOld LJShiku H. Humoral immune responses in patients vaccinated with HER2 protein complexed with a novel antigen delivery system of cholesteryl pullulan(CHP-HER2).
Cancer Research.
2006
-
Bauer SOosterwijk EStenner FRitter GScott AMOld LRenner C. Inhibition of solid tumor growth by intravenous administration of cG250-TNF immunocytokine.
Cancer Research.
2006
-
Lawrentschuk NRigopolous AMurone CLee TDavis IDScott AMBolton DM. A novel method for transplanting a reproducible volume of xenograft tumour beneath the renal capsule using automated biopsy equipment and an epidural needle.
BJU International.
10-10.
2006
-
Lawrentschuk NMurone CRigopolous AMountain AO'Keefe GJones GLee FTDavis IDScott AMBolton DM. In vivo tumour hypoxia and carbonic anhydrase IX expression in xenografted human renal cell carcinoma animal models using probes, I-124-G250 pet, biodistribution and immunohisto-chemistry immunobiodistribution, and oxygen studies.
BJU International.
10-10.
2006
-
Mitchell PScott AMO'Keefe GSaunder THicks RJPoon ABaum CBrega NMcCarthy TToner G. Assessment of tumor perfusion by (oxygen-15)-water PET imaging during treatment with sunitinib malate (SU11248) in patients with advanced malignancies.
Annals of Oncology.
32-33.
2006
-
Gong SJO’Keefe GJRykers KMantle CGunawardana DHRolfo AWada MScott AM. PET/CT Rigid-Body Registration in Radiation Treatment Planning Settings: Phantom Validation and Strategy Investigation.
Lecture Notes in Computer Science.
222-229.
2006
Full text if available -
Gan HKBurgess AWWalker FScott AMJohns TG. The epidermal growth factor receptor (EGFR) exists as an inactive dimer conformation that is reactive with mAb 806 and distinct from the "back-to-back" ligated dimer..
Clinical Cancer Research.
8995S-8995S.
2005
-
Scott AMMitchell PO'Keefe GSaunder THicks RJPoon ABaum CBrega NMcCarthy TToner G. Tumor perfusion as assessed by (oxygen-15)-water PET imaging during treatment with sunitinib malate (SU11248) in patients with advanced malignancies..
Clinical Cancer Research.
9129S-9129S.
2005
-
Scott ARigopoulos ALee FT. Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478.
Clinical Cancer Research.
7080s-7086s.
2005
Full text if available -
Cher LMurone CRamdave SHannah AO'Keefe GPathmaraj KTochon-Danguy HSachinidis JChan JBerlangieri SFabinyi GScott A. Correlation of hypoxic cell fraction with glucose metabolic rate and markers of angiogenesis and proliferation in gliomas.
Neuro-Oncology.
395-395.
2005
-
Johns TVitali AAPerera RMVernes SScott AM. Ligand-independent activation of the EGFRvIII: A naturally occurring mutation of the EGFR commonly expressed in glioma.
Neuro-Oncology.
299-299.
2005
-
Ackermann UArdipradja KLee FTTochon-Danguy HJYoung KScott AM. C-11 LABELLING AND BIODISTRIBUTION OF AG1478.
Journal of Labelled Compounds and Radiopharmaceuticals.
S132-S132.
2005
-
Kageyama SKitano SNagata YHiasa AMiyahara YImai HMurphy RScott AMHoffman EWOld LJShiku H. Phase I study of CHP-HER2 polyvalent cancer vaccine, HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysaccharides..
Journal of Clinical Oncology.
171S-171S.
2005
-
Falzon CLAckermann UWhite JMTochon-Danguy HJScott AM. SYNTHESIS AND RADIOLABELLING OF A NOVEL IMAGING AGENT FOR HYPOXIC TISSUE IN STROKE AND TUMOURS.
Journal of Labelled Compounds and Radiopharmaceuticals.
S198-S198.
2005
-
Lawrentschuk NLiu ZMurone CDavis IDScott AMBolton DM. Serum osteopontin - a new tumour marker in renal cell carcinoma.
BJU International.
27-27.
2005
-
Gong SJO'Keefe GJScott AM. Comparison and Evaluation of PET/CT Image Registration.
Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings.
1599-1603.
2005
Full text if available -
McKay MJTaylor CJohns TGCrvjelic ASolomon BXu HLScott AM. Anti-tumour effects of targeting a tumour-specific, truncated EGF receptor with a novel monoclonal antibody combined with radiation.
Radiotherapy and Oncology.
S372-S372.
2004
-
Johns TGPerera RMVitali AAVernes SScott A. Phosphorylation of a glioma-specific mutation of the EGFR.
Neuro-Oncology.
317-317.
2004
-
Perera RMNarita YFurnari FBTavarnesi MLLuwor RBBurgess AWStockert EJungbluth AAOld LJCavenee WKScott AMJohns TG. Treatment of human tumor xenografts with mAb 806 in combination with a prototypical EGFR-specific antibody generates enhanced anti-tumor activity.
Neuro-Oncology.
334-334.
2004
-
Sakamoto JOriuchi NMochiki EScott AMHoffman EJungbluth AAsao AKuwano HEndo KOld LJ. A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacolkinetics, immunohistochemistry, and quantitative tumor uptake.
Journal of Clinical Oncology.
348S-348S.
2004
-
Scott AMTebbutt NLee FTCavicchiolo TLiu ZPoon ABrechbiel MWStockert EHoffman EWOld LJ. Phase I trial of hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen..
Journal of Clinical Oncology.
179S-179S.
2004
-
Michael MMitchell PHicks RScott AEllis AThompson MHoskins JBates STebbutt NZalcberg JR. The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL)..
Journal of Clinical Oncology.
135S-135S.
2004
-
Shapira DRPower BECody SKiki TLee FTScott AMHudson PJ. In vitro binding and internalization of engineered single chain Fv antibody fragments of anti-Lewis Y humanized monoclonal antibody (hu3S193).
Cytometry.
138-138.
2004
-
Cebon JSDavis IDChen WParente PJackson HShackleton MHopkins WChen QYMurphy RTai TYDimopoulos NScott AMcArthur GMacgregor DMiloradovic LGreen SMaraskovsky ECuthbertson AMaher DMitchell SRitter GStockert EHoffman EWPugliese LOld LJ. NY-ESO-1 protein formulated with immunostimulatory complexes (ISCOM (R) adjuvant) in patients with minimal residual disease induces a broad-based immune response involving CD4 & CD8 T lymphocytes and high titered antibody..
Clinical Cancer Research.
6265S-6265S.
2003
-
Chong GLee FHopkins WMountain APotasz NMurphy RChappell BSchleyer PPapenfus TO'Keefe GJCebon PUJMitchell PPoon ABurgess AWHoffman EOld LJScott AM. Phase I radioimmunotherapy trial of I-131-huA33 in patients with advanced colorectal carcinoma..
Journal of Nuclear Medicine.
32P-32P.
2003
-
Jungbluth AAStockert EHuang SCollins VPCoplan KIversen KKolb DJohns TJScott AMGullick WJRitter GCohen LScanlan MJCavanee WKOld LJ. A new monoclonal antibody recognizing human cancers with amplification/over-expression of the human epidermal growth factor receptor.
Laboratory Investigation.
296A-297A.
2003
-
Jungbluth AAStockert EHuang SCollins VPCoplan KIversen KKolb DJohns TJScott AMGullick WJRitter GCohen LScanlan MJCavanee WKOld LJ. A new monoclonal antibody recognizing human cancers with amplification/over-expression of the human epidermal growth factor receptor..
Modern Pathology.
296A-297A.
2003
-
Markus RReutens DRRead SJKazui SHirano TWright PMChambers BCSachinidis JTochon-Danguy HScott AMDonnan GA. The ischaemic penumbra in human stroke: Topography and temporal evolution studied with F-18-misonidazole ((FMISO)-F-18) and positron emission tomography (PET).
Stroke.
257-258.
2003
-
Scott AM. Current status of positron emission tomography in oncology.
Journal of Medical Imaging and Radiation Oncology.
154-162.
2002
Full text if available -
Papenfuss ATChong GSchleyer PJChappell BO'Keefe GJScott AM. A model of I-131-huA33 pharmacodynamics in patients with colorectal carcinoma..
Journal of Nuclear Medicine.
210P-210P.
2002
-
Markus RReutens DCKazui SHirano TO'Keefe GJSachinidis JScott ADonner GA. Hypoxic potentially viable tissue surrounding intracerebral hemorrhage in humans identified by [F-18]-Fluoromisonidazole and positron emission tomography (PET).
Stroke.
362-362.
2002
-
Mishima KJohns TGLuwor RBScott AMStockert EJungbluth AAOld LJHuang HSCavenee WK. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of MAb 806, a novel monoclonal antibody directed to the receptor..
Clinical Cancer Research.
3784S-3784S.
2001
-
Scott AMWiseman GWelt SLee FTHopkins WMitchell PAdjei ADivgi CRLarson SMHoffman EWTanswell PBette PVlock DAmelsberg ARettig WOld LJ. A phase I dose-escalation study of BIBH-1 in patients with advanced or metastatic fibroblast activation protein positive cancer..
Journal of Nuclear Medicine.
311P-311P.
2001
-
Ramdave SThomas GBerlangieri SUBolton DMDavis IDTochon-Danguy HMacgregor DScott AM. Clinical role of F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the detection and management of renal cell carcinoma..
Journal of Nuclear Medicine.
80P-80P.
2001
-
Scott AMRamdave SHannah APathmaraj KTochon-Danguy HSachinidis JChan JBerlangieri SUFabinyi GCher LM. Correlation of hypoxic cell fraction with glucose metabolic rate in gliomas with F-18-fluoromisonidazole (FMISO)& F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)..
Journal of Nuclear Medicine.
67P-67P.
2001
-
Wiseman GAScott AMGansen DNLee FTHopkins WOld LJHoffman EWWarnaar S. Traced labeled I-131 chimeric clonal antibody (cG250) nv patients with renal cell carcinoma (RCC)..
Journal of Nuclear Medicine.
310P-310P.
2001
-
Papenfuss ATO'Keefe GJScott AM. Segmented attenuation correction in whole body PET using neighbourhood EM clustering.
IEEE Nuclear Science Symposium and Medical Imaging Conference.
2000
-
Scott ABERLANGIERI S. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer*1.
European Journal of Cardio-Thoracic Surgery.
S25-S30.
1999
Full text if available -
Lovqvist AHumm JLPentlow KSFinn RDJungbluth ALee FTScott AMLarson SM. Comparative biodistribution of In-111 and Y-86 labeled humanized monoclonal antibody 3S193..
Journal of Nuclear Medicine.
81P-82P.
1999
-
Read SJHirano TAbbott DFMarkus RSachinidis JITochon-Danguy HJBladin CFScott AMDonnan GA. A volumetric analysis of hypoxic tissue imaged with F-18-fluoromisonidazole PET after ischaemic stroke.
Stroke.
249-249.
1999
-
Read SJHirano TBladin CFSachinidis JITochon-Danguy HJEgan GFAbbott DFChan JGScott AMMcKay WJDonnan GA. Direct imaging of the ischaemic penumbra using F-18-fluoromisonidazole.
Stroke.
312-312.
1998
-
Catimel BNerrie MLee FTScott AMRitter GWelt SOld LJBurgess AWNice EC. Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen by the use of an optical biosensor.
Journal of Chromatography A.
15-30.
1997
Full text if available -
Barendswaard ECODonoghue JALarson SMTschmelitsch JWelt SSchlom JScott AHumm JL. Comparison of the effectiveness of radioimmunotherapy and fractionated radiotherapy..
Journal of Nuclear Medicine.
212-212.
1997
-
McKay WJScott AMBerlangieri S. The role of the PET scan in the diagnosis of ischaemic heart disease. A review.
11TH ASEAN CONGRESS OF CARDIOLOGY AND THE 5TH ASIAN-PACIFIC CONGRESS OF CARDIAC REHABILITATION.
161-164.
1997
-
Scott AMAkhurst TBerlangieri SUHannah AFox RZalcberg JCebon JMcLeish AJones RHardy KThomas DChan GTochonDanguy HEgan GFMcKay WJ. Comparison of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography in the detection of recurrent colorectal carcinoma..
Journal of Nuclear Medicine.
519-519.
1996
-
Berlangieri SUScott AMKnight SFitt GJPointon OHess EMPathmaraj KThomas DLOKeefe GJChan JGEgan GFTochonDanguy HJHennessy OFSinclair RAClarke CPMcKay WJ. F-18 fluorodeoxyglucose positron emission tomography and computed tomography in the mediastinal staging of lung carcinoma..
Journal of Nuclear Medicine.
474-474.
1996
-
Akhurst TScott AMBerlangieri SUHannah AJones RHardy KMcLeish AFox RZalcberg JPointon OCebon JThomas DChan GTochonDanguy HEgan GFMcKay WJ. Validation of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) with surgical pathology in the detection of recurrent colorectal carcinoma..
Journal of Nuclear Medicine.
515-515.
1996
-
DIVGI CRWELT SRETTIG WSCOTT AMGARINCHESA PCARMICHAEL NFALLONE PSFINN RDCOHEN AMOLD LJLARSON SM. RADIOIMMUNOSCINTIGRAPHY (RIS) OF HEPATIC METASTASES FROM COLORECTAL-CARCINOMA (CRC) USING I-131-LABELED MONOCLONAL-ANTIBODY (MAB) F-19.
Journal of Nuclear Medicine.
P83-P83.
1993
-
Scott A. 2019 SNMMI Highlights Lecture: Oncology and Therapy.
Journal of Nuclear Medicine.
11N-17N.
2020
-
conference poster
-
Chia PLCao DGan HReilly EPhillips AJohn TScott A. ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo.
Journal of Thoracic Oncology.
S759-S759.
2019
Full text if available -
Morigi JJRajadurai SFerdinandus JWelch JPathmaraj KPoon ABerlangieri SLee STScott AM. Quantitative Analysis of FDG PET/CT for Assessment of Therapy Response in Patients with Non-Small Cell Lung Carcinoma Treated with Nivolumab.
Internal Medicine Journal.
33-34.
2019
-
O'Keefe GPain CGong SChan JScott A. Should copper inserts be used for dose calibrator measurements?.
Internal Medicine Journal.
39-40.
2019
-
Traczyk JChappell BLivori AScott A. TITRATION OF (TECHNETIUM)-T-99M-MACROAGGREGATED ALBUMIN DOSES IN LUNG VENTILATION/PERFUSION IMAGING AND ITS EFFECT ON DOSE REDUCTION.
Internal Medicine Journal.
33-33.
2019
-
Tochon-Danguy HAckerman UPoniger SChan GMorris MLewis JLyashchenko SScott A. USE OF THE FLEXLAB RADIOSYNTHESISER FOR THE FULLY AUTOMATED SYNTHESIS OF 16B-[F-18]FLUORO-5A-DIHYDROTESTOSTERONE.
Internal Medicine Journal.
32-32.
2015
-
Leimgruber AHickson KLee STGan HCher LSachinidis JO'Keefe GScott AM. GLYOXIA: INTEGRATED ANALYSIS OF GLUCOSE METABOLISM AND HYPOXIA WITH F-18-FLUOROMISONIDAZOLE (FMISO) AND 18F-FLUORODEOXYGLUCOSE (FDG) PET IN HIGH GRADE GLIOMA PATIENTS.
Internal Medicine Journal.
26-27.
2012
-
Chia PLCao DGan HReilly EPhillips AJohn TScott A. ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo.
Journal of Thoracic Oncology.
S759-S759.
2019
-
editorial article
-
Scott A. 2018 SNMMI Highlights Lecture: Oncology and therapy.
Journal of Nuclear Medicine.
59:11N-18N.
2018
-
Lee STScott AM. Nuclear medicine in the era of personalised medicine.
Internal Medicine Journal.
48:497-499.
2018
Full text if available -
Lawrentschuk NCorfield JMScott A. Is choline-based PET imaging still relevant in recurrent prostate cancer?.
BJU International.
120:303-304.
2017
Full text if available -
LEE SZETINGSCOTT ANDREWM. Are we ready for dual-time point FDG PET imaging?.
Journal of Medical Imaging and Radiation Oncology.
55:351-352.
2011
Full text if available
-
Scott A. 2018 SNMMI Highlights Lecture: Oncology and therapy.
Journal of Nuclear Medicine.
59:11N-18N.
2018
-
erratum
-
Chang AYDao TGejman RSJarvis CAScott ADubrovsky LMathias MDKorontsvit TZakhaleva VCurcio MHendrickson RCLiu CScheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.
Journal of Clinical Investigation.
3557-3557.
2017
Full text if available -
Greening DWLee STJi HSimpson RJRigopoulos AMurone CFang CGong SO’Keefe GScott AM. Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
Oncotarget.
35497.
2016
Full text if available
-
Chang AYDao TGejman RSJarvis CAScott ADubrovsky LMathias MDKorontsvit TZakhaleva VCurcio MHendrickson RCLiu CScheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.
Journal of Clinical Investigation.
3557-3557.
2017
-
other publication
-
Scott ABodei LHerrmann KBaum RPKidd MMalczewska AModlin IM. Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus.
Journal of Nuclear Medicine.
7-8.
2019
Full text if available -
Ayati NJesudason SBerlangieri SUScott AM. Generalized Lymph Node Activation after Influenza Vaccination on 18F FDG-PET/CT Imaging, an Important Pitfall in PET Interpretation..
Asia Oceania Journal of Nuclear Medicine and Biology.
148-150.
2017
Full text if available -
Mertens LSMir MCScott AMLee STFioole-Bruining AVegt EVogel WVManecksha RBolton DDavies IHorenblas Svan Rhijn BWGLawrentschuk N. F-18-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Aids Staging and Predicts Mortality in Patients With Muscle-invasive Bladder Cancer (vol 83, pg 393, 2013).
Urology.
1447-1447.
2014
-
Scott ABodei LHerrmann KBaum RPKidd MMalczewska AModlin IM. Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus.
Journal of Nuclear Medicine.
7-8.
2019
-
abstract
-
Gan HSeow ALau ESze-Ting LAmeratunga MPerchyonok YCao DRigopoulos ALee H-JGomez EMaag DScott A. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414.
Neuro-Oncology.
24-24.
2018
-
Saunus JMKalita-de Croft PLee FTAl-Ejeh FLim MEnsbey KNiland CJeffree RLThomas PDay BWRose SScott AMLakhani SR. INVESTIGATING THE HER2-3 DIMER AS A THERANOSTIC TARGET IN BRAIN METASTASES.
Asia Pacific Journal of Clinical Oncology.
114-114.
2016
-
Scott ABurvenich ILee FO'Keefe GMakris DCao DGong SRigopoulos AAllan LBrechbiel MLiu ZRamsland P. Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers.
Internal Medicine Journal.
19-19.
2016
-
Nadebaum DLee SNikfarjam MScott A. METASTATIC CLEAR CELL RENAL CELL CARCINOMA DEMONSTRATING FOCAL UPTAKE ON (68)GA-DOTATATE PET.
Internal Medicine Journal.
37-37.
2016
-
Gong SLee SDavis IO'Keefe GBolton DClouston DDamianovich DPezaro CAngus DTochon-Danguy HChan JJenkins TFong CScott A. SEXTANT ANALYSIS OF [C-11] CHOLINE PET UPTAKES IN PROSTATE OF PATIENTS UNDERGOING NEOADJUVANT DOCETAXEL CHEMOTHERAPY: VALIDATION OF SUV, SUVR, K-I AND BPND IN ASSESSING TREATMENT RESPONSE.
Internal Medicine Journal.
39-39.
2016
-
Gong SJO'Keefe GJLee STAkhurst TLee FTDavis IWeickhardt AGan HPathmeraj KHicks RJHudson PJScott AM. DOSIMETRY OF I-124-PEG-AVP0458 DIABODY IN PATIENTS WITH TAG-72 POSITIVE OVARIAN OR PROSTATE CANCER.
Internal Medicine Journal.
40-41.
2015
-
Gan HSeow ALau ESze-Ting LAmeratunga MPerchyonok YCao DRigopoulos ALee H-JGomez EMaag DScott A. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414.
Neuro-Oncology.
24-24.
2018